Transmissible spongiform encephalopathies: The identification of a new disease phenotype after experimental interspecies transmission by Kokemuller, Robyn
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2018
Transmissible spongiform encephalopathies: The
identification of a new disease phenotype after
experimental interspecies transmission
Robyn Kokemuller
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Neuroscience and Neurobiology Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Kokemuller, Robyn, "Transmissible spongiform encephalopathies: The identification of a new disease phenotype after experimental
interspecies transmission" (2018). Graduate Theses and Dissertations. 16728.
https://lib.dr.iastate.edu/etd/16728
Transmissible spongiform encephalopathies: The identification of a 
new disease phenotype after experimental interspecies transmission 
 
by 
 
Robyn Kokemuller 
 
 
A thesis submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of  
MASTER OF SCIENCE 
 
Major: Neuroscience 
 
Program of Study Committee: 
M. Heather West Greenlee, Major Professor 
Justin J. Greenlee 
Jodi Smith 
 
 
 
The student author, whose presentation of the scholarship herein was approved by the 
program of study committee, is solely responsible for the content of this thesis. The 
Graduate College will ensure this thesis is globally accessible and will not permit 
alterations after a degree is conferred.  
 
 
 
Iowa State University 
Ames, Iowa 
2018 
 
 
 
 
Copyright © Robyn Kokemuller, 2018. All rights reserved. 
	 ii	
TABLE OF CONTENTS  
             
LIST OF TABLES …........................................................................................... iv 
LIST OF FIGURES ………………………………………………………………….. v 
ABSTRACT ………………………………………………………………………….. vi 
CHAPTER 1. INTRODUCTION 
 Thesis Organization ………………………………………………………… 1 
 Introduction ………………………………………………………………….. 1 
 Literature Review …………………………………………………………… 3 
  Prions ………………………………………………………………… 3 
  Physiological role of PrPC ……………………………………..…… 4 
  Transmissible Spongiform Encephalopathies (TSEs) …………... 5 
  TSE Detection ……………………………………………………..... 7 
   Immunohistochemistry ……………………………………... 8 
   Western Blot and Enzyme Immunoassay ………………... 8 
   Vacuolation Profiling ……………………………………...... 10 
  Scrapie ………………………………………………….……………. 10 
  Scrapie Strains ……………………………………….……………… 11 
   US No.13-7 ………………………………….……………….. 12 
   x124 Scrapie ………………………………….…………..…. 12 
   SSBP/1 …………………………………………….…………. 13 
   Atypical Scrapie (Nor98) ……………………….…………… 14 
  Chronic Wasting Disease ……………………………….………….. 14 
  Mouse Models ………………………………….……………………. 15 
  Strain Variation ……………………………….……………………… 16 
  Interspecies Transmission …………………….……………………. 17 
 References ……………………………………………….………………...... 18 
CHAPTER 2. THE PHENOTYPE OF SHEEP SCRAPIE IS CHANGED UPON 
EXPERIMENTAL PASSAGE THROUGH WHITE-TAILED DEER 
 Abstract ………………………………………………………………………. 32 
 Introduction ………………………………………………………………...... 33 
 Methods and Materials …………………………………………………...... 34 
 Results ……………………………………………………………………….. 39 
 Discussion ……………………………………………………………….…… 45 
 Conclusion ………………………………………………………….………… 51 
 Acknowledgments ……………………………………………………........... 52  
 References ……………………………………………………………..…….. 52 
	 iii	
 Tables ………………………………………………………………………... 56 
 Figures ……………………………………………………………………….. 60 
CHAPTER 3. GENERAL CONCLUSIONS 
 Summary ……………………………………………………………………... 69 
 Future Research …………………………………………………………….. 70 
 Concluding Remarks ………………………………………………………... 71 
 
  
	 iv	
LIST OF TABLES 
Table 1 WTD scrapie inocula EIA data ……………………………………… 57 
Table 2 EIA data for mouse bioassay inocula ……………………………… 57  
Table 3 Brain region EIA results …………………………………………….. 58 
Table 4 Brain regions scored for spongiform change …………………….. 59  
Table 5 PrPSc distribution in sheep inoculated with the scrapie agent  
derived from deer ………………………………………………….… 60  
  
	 v	
LIST OF FIGURES 
Figure 1 Western blot of sheep with clinical signs after inoculated  
with the WTD scrapie agent ……………………………………........ 61 
 
Figure 2 PrPSc deposition in brain regions varies with sheep PRNP  
genotype and source of inoculum ….............................................. 62 
 
Figure 3 Quantitative analysis of PrPSc present in brainstem,  
cerebellum, and neocortex …........................................................ 63 
 
Figure 4 Gray matter vacuolation profile for sheep inoculated with the  
WTD scrapie agent …………………………………………………... 64 
 
Figure 5 Association of vacuolation, EIA, and immunohistochemistry  
data with results by sheep genotype and inoculum source …….. 65 
 
Figure 6 Reduction in No.13-7 incubation period after passage  
through deer …………………………………………………….……. 66 
 
Figure 7 Comparison of PrPSc accumulation between scrapie strains …... 67 
 
Figure 8 Summary of the original No.13-7 scrapie isolate serial  
passages …………………………………………………………..…. 68  
	 vi	
ABSTRACT 
 Transmissible spongiform encephalopathies (TSEs) are neurodegenerative 
diseases that affect both humans and animals. TSEs, or prion diseases, are associated 
with the accumulation of the misfolded prion protein (PrPSc) in central and peripheral 
nervous system, and lymphoid tissues. Accumulation of PrPSc results from the 
misfolding of the normal, cellular prion protein (PrPC) to the disease-associated form 
(PrPSc). TSEs have strain variations that can affect host susceptibility, incubation period, 
and disease phenotype, including PrPSc accumulation intensity and patterning. These 
strain variations also influence interspecies transmission. It has been demonstrated that 
white-tailed deer are susceptible to the scrapie agent (the TSE of sheep). However, 
sheep are not very susceptible to the CWD agent. The purpose of this thesis was to 
determine the susceptibility of sheep to the scrapie agent derived from white-tailed deer 
(WTD-scrapie).  
 Suffolk sheep of various genotypes were challenged oronasally with the WTD-
scrapie agent from either deer cerebrum or brainstem at the level of the obex. We found 
that sheep with a valine (V) at codon 136 (VV136) of the prion protein (PRNP) had a 
shorter incubation period than sheep with an alanine (A) at codon 136 (AA136). This 
result is in contrast to the original sheep scrapie agent that had a faster incubation 
period in AA136 sheep. We observed differences in PrPSc accumulation intensity and 
spongiform change between sheep of different genotypes challenged with the same 
inoculum source and sheep of the same genotype challenged with different inocula. We 
also demonstrated that inocula prepared from sheep challenged with the WTD scrapie 
agent resulted in a reduced incubation period in transgenic mice expressing ovine 
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PRNP when compared to the original sheep scrapie isolate. The results presented in 
this thesis demonstrate that sheep are susceptible to the scrapie agent derived from 
WTD and the phenotype of disease is different than the original sheep scrapie inoculum 
source.   
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CHAPTER 1. GENERAL INTRODUCTION  
Thesis organization 
 This thesis includes one manuscript relevant to this degree that will be submitted 
for publication in a peer-reviewed journal. Prior to the manuscript, I will present the 
significance of this research topic and provide a review of the literature. The manuscript 
will be followed by an overview discussion of the findings, prospective for future work, 
and general conclusions.  
Introduction 
Transmissible spongiform encephalopathies (TSEs; prion diseases) are fatal 
neurodegenerative diseases. Disease results from the misfolding of the normal, cellular 
prion protein (PrPC) to the diseased-associated form (PrPSc) (Prusiner, Science1991). 
TSEs are known to affect cattle (bovine spongiform encephalopathy), humans 
(Creutzfeldt-Jakob disease), deer (chronic wasting disease), and sheep (scrapie). Prion 
diseases are typically diagnosed post-mortem by histopathology, western blot analysis, 
and enzyme immunoassay. In addition to these techniques, we also can study the 
spongiform change and incubation period to determine a disease’s phenotype. TSE 
agents have strain variations that can influence disease phenotype. Differences can be 
detected in the immunoreactivity pattern, the molecular mass of the protein, the lesion 
profile, and the incubation period. These strain variations can have an affect on the 
susceptibility of animals to disease with prion protein polymorphisms as well as potential 
interspecies transmission (Sigurdson, Nat Met 2007).  
Sheep are variably susceptible to scrapie depending on their prion protein gene 
(PRNP) sequence. Sheep have amino acid polymorphisms that affect susceptibility to 
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the scrapie agent at 3 major codons in the PRNP. These polymorphisms consist of: 
valine (V) or arginine (R) at codon 136, histidine (H) or arginine (R) at codon 154, and 
glutamine (Q) or arginine (R) at codon 171. Sheep susceptible to scrapie is associated 
with having alleles V136R154Q171 and A136R154Q171, whereas sheep with alleles 
A136R154R171 are known to be resistant to scrapie (Goldmann, J Gen Virol 1994). The 
most influential codon is 171, where QQ171 is associated with susceptibility and RR171 
is resistant (Greenlee, ILAR 2015). This work demonstrates that differences in the 
PRNP gene can have an effect on susceptibility, disease phenotype, and the incubation 
period.  
Sheep and deer can share the same geographical region so it is important to 
understand the potential for interspecies transmission between these species. 
Experimental studies have demonstrated that sheep are not very susceptible to the 
CWD agent. Sheep intracranially inoculated with white-tailed deer CWD (4 out of 15; 
Greenlee unpublished) or mule deer CWD (2 out of 10, respectively; Hamir, JVDI 2006) 
demonstrated a low attack rate. Oronasal inoculation of CWD to sheep has to date been 
unsuccessful (study currently at 50 MPI). In contrast, experimental studies have 
demonstrated that white-tailed deer are highly susceptible to the scrapie agent. Deer 
intracranially or oronasally inoculated with the scrapie agent had a 100% attack rate 
(Greenlee, Vet Res 2011; Greenlee submitted). This work uses Suffolk sheep of various 
genotypes and transgenic mice expressing ovine PRNP to determine the susceptibility 
of sheep to the scrapie agent derived from white-tailed deer. 
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Literature Review 
Prions  
In 1991, Stanley Prusiner proposed the prion hypothesis that stated that a protein 
is necessary and is also the source of prion diseases (Prusiner, Science1991). He was 
later awarded the Nobel Prize in 1997 for his work (Prusiner, Proc Natl Acad Sci 1998). 
Prusiner coined the termed “prion” to describe the proteinaceous infectious particles 
that caused scrapie and Creutzfeldt-Jakob disease. Prion proteins are composed of a 
normal, cellular version of the protein (PrPC), that is highly conserved and is protease-
sensitive. However, the disease-associated form of the protein, PrPSc is protease 
resistant.  
Hamsters have been used to study prion diseases (Chandler, Vet Res Sci 1972; 
Kimberlin, J Infect Dis 1975). Stanley Prusiner used a hamster model to do much of his 
early work involving scrapie, which helped him identify and classify the prion protein 
(Prusiner, Prog Clin Biol Res 1980; Prusiner, Biochemistry 1980; Prusiner, Proc Natl 
Acad Sci 1981). Protein purification performed on scrapie-diseased hamsters revealed 
the molecular mass of the prion protein (Prusiner, 1998). Infectivity analysis using 
sucrose gradients on the scrapie-infected hamster tissue, found that the infectious 
agent was localized near the bottom of the enriched fraction (Bolton, Science 1982). 
Further analysis of this agent through radioiodination and gel electrophoresis, revealed 
that the prion protein (PrP) band had a molecular size of 27,000 to 30,000 daltons (27-
30 kDa), giving it the reference name of PrP 27-30 (Prusiner, Biochem 1982). Using a 
cDNA library and Southern blot analysis it was demonstrated that PrP 27-30 was 
encoded by a chromosomal gene (Oesch, Cell 1985). It was also demonstrated that the 
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chromosomal gene that encodes the PrP 27-30 fragment also encodes the cellular form 
of PrP (PrPC; Basler, Cell 1986). The unchanged levels of PrP messenger RNA (mRNA) 
throughout the course of disease led to the identification of PrPC and to the notion that 
conversion of PrPC to PrPSc is a post-translational process (Prusiner, 1991).  
Physiological Role of PrPC 
The physiological role of PrPC is thought to be involved in many processes. Mice 
that are devoid of the prion protein have been generated to help in understanding the 
role of PrPC. These mice are generated by disruptive modifications in the open reading 
frame (ORF) of the prion protein (Weissman, Br Med Bull 2003; Bueler, Nature 1992; 
Manson, Mol Neurobiol 1994). PrP knockout (PrP-/-) mice do not display any abnormal 
behaviors, phenotypic deficits, and showed normal development and reproduction, 
suggesting that the prion protein is not an essential protein (Manson, 1994; Jackson, 
PLoS One 2014; Nuvolone, J Exp Med 2016). PrPC has been suggested to play a part 
in peripheral nerve myelination, and in neuroprotection against neurotoxic stimuli 
(Watts, Acta Neuropathol 2017). All PrP-/- mice generated have an age-related onset of 
chronic demyelinating polyneuropathy (CDP) in their peripheral nerves (Bremer, Nat 
Neurosci 2010; Nishida, Lab Investig 1999). Interestingly, it was also demonstrated that 
this phenotype is restored by re-introduction of PrPC expression (Bremer, Nat Neurosci 
2010) confirming the role of PrPC in the myelination of peripheral nerves.  
It has also been demonstrated that PrPC can have a neuroprotective role. In 
some cases, when PrPC is expressed the cell is resistant to apoptosis (Diarra-Mehrpour, 
Caner Res 2004). Other research has demonstrated that PrPC can act against apoptotic 
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stimuli in various cell lines (Bounhar, J Biol Chem 2001; Kim, Brain Res Mol 2004; 
Kuwahara, Nature 1999; Roucou, Cell Death Differ 2005; Yu, PLoS One 2012). 
In addition, PrP knockout studies in mice have demonstrated that PrPC is 
required for the propagation of prion disease (Moreno, Prions Met 2017; Bueler, Cell 
1993; Prusiner, Proc Natl Acad Sci 1993; Sailer, Cell 1994). PrP-/- mice challenged with 
scrapie failed to develop disease (Bueler, Cell 1993). There is also evidence that the 
amount of PrPC present in the brain has an influence on disease phenotype (incubation 
period, immunoreactivity intensity and patterns, molecular mass of the prion protein, 
and spongiform change). In the early stages of disease, high amounts of PrPSc 
accumulate in the brain independent of the amount of PrPC present, which has been 
demonstrated in transgenic mouse lines that express different levels of PrPC (Bueler, 
Mol Med 1994; Sandberg, Nature 2011; Watts, Acta Neuropathol 2017). However, once 
the maximal amounts of PrPSc have accumulated, the phenotype of the disease is 
proportional to the amount of PrPC present in the brain (Sandberg, Nature 2011; 
Sandberg, Nat Commun 2014).  
Transmissible Spongiform Encephalopathies (TSEs) 
 TSEs are typically spread through infectious forms of the prion but there also are 
inherited or sporadic forms. Human prion diseases consist of: sporadic CJD (sCJD), 
variant CJD (vCJD), familial Creutzfeldt-Jakob disease (fCJD), fatal familial insomnia 
(FFI), Gerstmann–Sträussler–Scheinker syndrome (GGS), and kuru. The sporadic, or 
irregular form of disease is most common among human CJD case with a rate of about 
85-90% of total CJD cases (Geschwind, Continuum 2015). sCJD is typically classified 
by the molecular mass profile of the abnormal isoform of the prion protein that differs 
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from vCJD (Kobayashi, Acta Neuropathol Comm 2013). vCJD was the result of 
ingestion of cattle infected with bovine spongiform encephalopathy (BSE) (Ironside, 
Folia Neuropathol 2012). Familial CJD is the inherited form of human prion disease, and 
are associated with having mutations in the prion protein gene (Lee, BMC Med 
Genomics 2014).  
Animal TSEs include: bovine spongiform encephalopathy (BSE) in cattle (Wells, 
Vet Rec1987), chronic wasting disease (CWD) in deer and elk (Williams, Vet Pathol 
2005), scrapie in sheep and goats (Cullie, 1939; Fast and Groshup 2013) and 
transmissible mink encephalopathy (TME) in mink (Ekroade, 1973). These TSEs are 
most commonly transmitted through the ingestion of the infectious form of the protein 
from contaminated feedstuff. In addition, CWD also can be also be transmitted within 
the environment when exposed to a carcass, blood, or excreta from a diseased animal 
like in the cases of chronic wasting disease (Williams, Vet Pathol 2005).  
 The “species barrier” influences efficiency of interspecies transmission of TSEs 
and is partially dependent on the prion protein (PRNP) gene sequence (Hagiwara, J 
Biochem 2013). Efficient transmission between species can be associated with a weak 
species barrier, whereas inefficient transmission between species can be correlated to a 
strong species barrier. Strength of the species barrier can be correlated to the 
similarities or differences between the PRNP gene sequence of the donor PrPSc and 
host PrPC, in addition to the conformation properties of the β2-α2 loop of the prion 
protein (Sigurdson, J Clin Invest 2010). Similar β2-α2 loops were correlated with efficient 
transmission, while β2-α2 loops that were not similar did not lead to transmission 
(Sigurdson, J Clin Invest 2010; Bett, FASEB 2012). In a comparison study, mice that 
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express the wild-type (WT) prion protein developed disease when challenged with 
scrapie or BSE, but mice that express a prion protein that produces a rigid loop (RL) did 
not develop disease (Sigurdson, J Clin Invest 2010).  
PRNP also has an influence on intraspecies susceptibility, incubation period, and 
disease phenotype (Lloyd, Top Curr Chem 2011). Each TSE strain can have variations 
that affect disease phenotype. These strain variations can be studied on the basis of 
incubation period (Bruce, BrMed Bull 1993), histopathology (Moore, vet path 2016) and 
vacuolation profiling (Bruce, BrMed Bull 2003). When experimentally transmitted to 
mice, TSE agents can have different incubation periods that help identify multiple 
strains from the same source (Morales, BBA 2007; Westaway, Cell 1987; Bruce, 
Techniques in Prion Res 2004). Histopathology was used in cases of natural scrapie in 
sheep with the same genotype to discern between multiple strains of scrapie due to the 
immunoreactivity patterns of PrPSc that were present (Gonzalez, J Gen Virol 2010). The 
severity and location of the spongiform change can be determined by vacuolation 
profiling and can be used to discriminate between different strains of scrapie. This 
technique has been used to distinguish disease phenotypes in cases of natural scrapie 
in sheep of the same genotype (Ligios, J Comp Pathol 2002).  
TSE Detection 
 TSEs are typically diagnosed postmortem by the detection of PrPSc in the central 
nervous system (Spiropoulos, Neuropath 2007) and in some species, the lymphoid 
system (Jeffrey, J Pathol 2006). Currently, immunohistochemistry, western blot, and 
enzyme immunoassays are used to detect PrPSc in tissues. Antemortem diagnosis is 
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accomplished in some species, like sheep, goats, and deer by taking rectal mucosal 
biopsy samples for histological examination (Spraker, J Vet Diagn Invest 2009).  
 Immunohistochemistry 
Immunohistochemistry (IHC) uses antibodies against the prion protein to detect 
PrPSc. The abnormal form of the prion protein can accumulate in different regions of the 
brain and in different cell types, resulting in a variety of immunolabeling patterns. 
Immunolabeling types consist of: granular, which can be found in the neuropil (network 
of neuronal axons, dendrites, and neuroglial that forms most the CNS grey matter) and 
presents as small particulate PrPSc deposits; aggregates, which also can be found in the 
neuropil but is a dense deposition of PrPSc and has a focal point that can vary in size; 
intraneuronal type can be found within the cytoplasm of larger neurons and appears as 
having small granular-like PrPSc deposits; stellate patterning, which is associated with 
glial cells within the neuropil and appears as radiating deposits of PrPSc (Corda, Vet Res 
2012). These patterns of PrPSc in different brain regions can be profiled and help 
distinguish between different strains of the same TSE (like scrapie; Moore, Vet Pathol 
2016) or between different TSEs (BSE compared to scrapie; Bencsik, PLoS One 2011).  
 Western Blot and Enzyme Immunoassay 
Since PrPSc is protease resistant, a western blot can be done utilizing proteinase 
K digestion prior to electrophoresis. Proteinase K removes the PrPC from the sample, 
leaving only PrPSc. This will determine if a sample is PrPSc positive and the molecular 
mass of the protein (Konold, BMC Vet Res, 2006). The PrP molecule has two possible 
glycosylation sites at residues 180 and 196 that are variably occupied and can be di-, 
mono-, or unglycosylated (Piro, J Virol 2009; Endo, Biochemistry 1989; Locht, Proc Natl 
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Acad Sci 1986). TSE strains may have different molecular masses that allow us to 
discern the TSE origin (Martin, BMC Vet Res 2009). In addition, multiple strains of BSE 
can be differentiated using western blot analysis. The two atypical forms of BSE have a 
molecular mass that differs from classical BSE (Greenlee, ILAR 2015). H-type (high-
type) BSE has a higher molecular mass of the unglycosylated PrPSc band compared to 
that of classical BSE (Biacabe, EMBO 2004; Biacabe, Prion 2007). L-type (low-type) 
BSE has a lower molecular mass of the unglycosylated PrPSc compared to that of 
classical scrapie (Balkema-Buschmann, J Toxicol Environ Health 2011; Konold, BMC 
Vet Res 2012). 
Enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA) 
were initially developed as a rapid screening test for livestock due to the BSE epizootic 
events in the United Kingdom (Smith, Am J Vet Res 2014). EIA uses an antigen-capture 
plate to detect misfolded protein in brain, lymphoid, or spleen tissues. The plate consists 
of an immobilized PrPSc-specific ligand that allows for the binding of the PrPSc 
conformer when present. PrPSc can then be detected using PrP-specific antibodies 
(IDEXX, BSE-scrapie insert). The enzyme-linked immunoassay (ELISA) by BioRad was 
approved as a diagnostic tool for CWD in October 2002 (Bio Rad, 2003). A field 
validation study was then published in 2003 to assess the ELISA test for detecting CWD 
in retropharyngeal lymph nodes (RLN) or obex from deer (Hibler, J Vet Diagn Invest 
2003). Recently, it also was demonstrated how ELISA can be used for detection of 
PrPSc in retropharyngeal lymph nodes of sheep with different genotypes (Kittelberger, N 
Z Vet J 2014). In addition, other tissues like the retina have been tested for the 
presence of PrPSc (Smith, Am J Vet Res 2014).  
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Vacuolation Profiling 
Vacuolation profiling is another diagnostic tool for TSEs and can be correlated to 
the progression of PrPSc accumulation (Begara-McGorum, J Comp Path 2002). 
Spongiform change is caused by the vacuolation of neuronal cell bodies or the loss of 
neuronal projections in the white matter of the brain. Spongiform change can present 
with different patterns that can be characterized for a particular TSE (Gonzalez, J Comp 
Path 2002). This spongiform change can be assessed in specific neuroanatomical 
locations and semiquantiatively “scored” based on the severity of the vacuolation. 
These scores are then graphed by score vs. location to determine the lesion profile 
(Simmons, Vet Rec 1996) that can then be used to differentiate between TSE origins 
(e.g. BSE and scrapie) depending on the PrPSc vacuolation profile (Jeffrey, Acta 
Neuropathol 2011).  
Scrapie 
 Scrapie was the first TSE identified and was described as early as 1732 (Irman, 
Virol 2011). The word scrapie is derived from Scottish origin and refers to the act of 
rubbing or scraping against objects (Plummer, Can J Comp Med Vet 1946). Sheep with 
scrapie may also show signs of biting the flank and hind legs, circling, failure to eat, and 
lameness (Brown, BMJ Brit Med J 1998).  Susceptibility or resistance of sheep to 
scrapie is determined largely by polymorphisms at three codons in the PRNP sequence 
(136, 154, and 171). Polymorphisms consist of valine (V) or alanine (A) at codon 136, 
arginine (R) or histidine (H) at codon 154, and arginine (R) or glutamine (Q) at codon 
171. Sheep susceptible by natural routes of exposure to scrapie are known to have the 
alleles V136R154Q171 and A136R154Q171 while sheep with alleles A136R154R171 are very 
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resistant and A136H154Q171 are somewhat resistant to scrapie (Baylis, Curr Mol Med 
2004). The genotype of sheep is known to have an affect on PrPSc immunolabeling. In 
cases of sheep with natural scrapie, sheep of the ARQ/ARQ genotype had more glial 
and intraglial-type accumulation whereas sheep of the VRQ/VRQ genotype had more 
granular and coalescing, or aggregate-like accumulation (Spiropoulos, Neuropath 
2007). Polymorphisms in the PRNP gene also have an affect on interspecies 
transmission of disease. Sheep with at least one valine (V) at codon 136 were more 
susceptible to BSE (VV136, 1 out of 1; AV136, 1 out of 1) compared to sheep with two 
copies of alanine (A) at codon 136 that were less likely (AA136, 1 out of 3) to develop 
disease when challenged with BSE (Goldmann, J Gen Virol 1994).  
 Scrapie was one of the first TSEs to be experimentally transmitted to other 
species (Cutlip, JID 1994). Scrapie has been successfully transmitted to cattle (Hamir, 
JVDI 2011), white-tailed deer (Greenlee, Vet Res 2011), elk (Hamir, JVDI 2004), 
raccoons (Hamir, Vet Rec 2003), pigs (Greenlee, Food Safety Comm 2016), and mice 
(Chandler, Lancet 1961). Although mice are not a natural host of scrapie, early 
transmission studies have lead to the identification of strain variations that have since 
been studied in depth (Bruce, Mol Neurobiol 1994; Beck, Vet Res 2012).  
Scrapie Strains 
 There are multiple scrapie strains that have been thoroughly investigated by 
experimental studies. The strains come from vast geographical regions including the 
United States (No.13-7, x124), United Kingdom (SSBP/1), and Norway (Nor98).   
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US No.13-7 
 The US No.13-7 scrapie strain is an isolate that was made from a pool of 13 
scrapie-affected Suffolk sheep from 7 source flocks, all sheep having the genotype 
ARQ/ARQ (Hamir, JVDI 2005). The No.13-7 isolate was used to intracranially challenge 
sheep of the ARQ/ARQ genotype for four serial passages. The strain stabilized after 
this fourth passaged with a mean incubation time of 10.7 months-post inoculation (MPI) 
(Hamir, Infect Dis 2009). This isolate was also transmitted experimentally in genetically 
susceptible sheep by three different routes: peritoneal, conjunctival, and nasal (Hamir, 
Vet Pathol 2008).  
This strain also has been used to intranasally challenge sheep of various 
genotypes (AA136, AV136, and VV136). Sheep of the AA136 genotype had an average 
incubation period (IP) of 20.1 months; sheep of the AV136 genotype had an IP of 22.8 
months; and sheep of the VV136 had an IP of 26.7 months (Moore, Vet Pathol 2016). 
PrPSc accumulation was widespread throughout the central nervous system (CNS), 
enteric nervous system, and in the lymphoreticular system (Hamir, Infect Dis 2009; 
Moore, Vet Pathol 2016). These results demonstrate that the No.13-7 scrapie has a 
faster incubation period in sheep of the AA136 genotype.  
x-124 scrapie  
A more recently identified US scrapie strain is known as x124 scrapie. This strain 
was found after sheep of various genotypes were challenged with an inoculum made 
from a pool of seven sheep with different genotypes; 5 sheep had the genotype 
ARQ/ARQ, 1 sheep had the genotype ARQ/VRQ, and one sheep had the genotype 
VRQ/VRQ (Bulgin, AJVR 2006). Sheep with the genotype AV136 were the first to 
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develop clinical disease and had an incubation period of 9 to 11 months, whereas the 
first sheep with the AA136 genotype develop clinical signs at 27 MPI, no sheep of the 
VV136 genotype were challenged (Bulgin, AJVR 2006). They suggested this faster 
incubation time was influenced by the presence of valine (V) at codon 136.  
When a second passage of x124 was intracerebrally inoculated in sheep of 
various genotypes, sheep of the VV136 or AV136 genotype were the first to develop 
disease at an average of 4.3 and 5.6 MPI, respectively, compared to sheep of the 
AA136 genotype that developed clinical disease at a mean of 14.3 MPI (Hamir, Vet 
Pathol 2009). When sheep were challenged oronasally with x124, the sheep of the 
VV136 genotype were the first to develop clinical disease at 6.9 MPI, sheep of the 
AV136 genotype had an incubation period of 11.9 MPI, and AA136 sheep did not 
develop disease or have evidence of PrPSc accumulation (Moore, Vet Pathol 2016). 
 SSBP/1 
 The SSBP/1 (Scrapie Sheep Brain Pool number 1) was derived from the 
Neuropathogenesis Unit in the UK and has been used to experimentally challenge 
Cheviot sheep since the 1960s (Hunter, Br Med Bull 2003). Sheep with the VV136 
genotype had the fastest incubation period of 160 days when challenged 
subcutaneously with SSBP/1; sheep that are heterozygotes at codon 136 (VRQ/ARQ or 
VRQ/ARR) had an incubation period of 260 and 360 days respectively; and sheep 
homozygous for alanine at 136 (AA136) were resistant to disease (Houston, J Gen Virol 
2002; Goldmann, J Gen Virol 1991). SSBP/1 PrPSc can be found throughout the CNS in 
sheep challenged with SSBP/1 (Houston, PLoS One 2015) and the lymphoreticular 
system (Gossner, Vet Microbiol 2011).  
	 14	
 Atypical (Nor98) Scrapie  
  Atypical scrapie was first described in Norway in 1998 (Benestad, Vet Rec 
2003). This strain was denoted atypical because the disease phenotype differed from 
that of classical scrapie. Atypical scrapie presented with different clinical features, PrPSc 
distribution, and immunoreactivity patterns, the genotype of sheep affected, and 
epidemiology (Benestad, Vet Res 2008). Atypical scrapie also presents with a different 
molecular mass profile compared to that of classical scrapie. Atypical scrapie has a 5-
band profile with a prominent band at 12 kDa, whereas classical scrapie has a 3-band 
profile with the unglycosylated band at 19-21 kDa (Hayashi, Biochem Biophys Res 
Commun 2005; Hope, J Gen Virol 1999; Sommerville, J Gen Virol 1990). When 7 field 
cases of atypical scrapie were analyzed in sheep of various genotypes, five of the 
seven sheep had PrPSc accumulation in the brain, but did not have evidence of PrPSc 
accumulation in the lymphoreticular system (Andreoletti, PLoS Pathog 2011). This 
differs from classical scrapie that has PrPSc throughout the brain and lymphoreticular 
system and would make early detection of atypical scrapie more challenging.  
Chronic Wasting Disease 
 Chronic wasting disease (CWD) is a TSE of cervids (deer and elk) that was 
identified in Colorado and Wyoming in 1967 (Haley, Annu Rev 2015). Symptoms of 
CWD include: progressive weight loss, locomotive changes, head tremors, altered head 
placement, and ataxia (Gilch, Top Curr Chem 2011). The CWD agent is efficiently 
transmitted horizontally, when naïve deer come into contact with an affected deer’s 
excreta (Williams, Vet Pathol 2005; Moore, Emerg Infect Dis 2016). The CWD agent 
has been found in urine, blood, saliva, feces, and velvet (Saunders, Emerg Infect Dis 
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2012; Mathiason, Science 2006; Miller, Emerg Infect Dis 2004; Mathiason, PLoS One 
2009). Zoonotic transmission of CWD to humans has been an increasing concern since 
BSE is transmissible to humans. However, studies using transgenic mice expressing 
the human PRNP sequence support that CWD is not transmissible to humans since the 
mice did not develop disease or present with TSE features even after 756 days 
(Sigurdson, Vet Res 2008; Kong, J Neurosci 2005).  
Another concern is the possible transmission of CWD to sheep as cervids and 
sheep can share the same grazing lands. Experimental transmission of mule deer CWD 
to sheep by intracranial route had a low attack rate (2 out of 10 positive for disease; 
(Hamir, JVDI 2006). This study suggested that susceptibility of sheep to CWD might be 
dependent on sheep genotype, as one of the sheep that developed clinical signs had 
the genotype AV136 (Hamir, 2006). The other PrPSc positive sheep (AA136; 72 MPI) 
had evidence of PrPSc by IHC and WB but did not show signs of clinical disease and 
was euthanized at the end of the study (Hamir, 2006). White-tailed deer- and elk-
derived CWD, was not transmissible to transgenic mice expressing ovine PRNP 
(Tg338; VRQ) (Madsen-Bouterse, J Gen Virol 2016). These studies suggest that 
transmission of CWD to sheep is unlikely, but could be possible depending on the 
source of the agent and the host sheep genotype.  
Mouse Models 
 Experimental transmission of scrapie to mice was reported as early as 1963 
(Chandler, Res Vet Sci 1963). Wild-type mice are the standard to identify and 
characterize TSE strains. The incubation period is a primary characterization tool for 
studying TSE strains. For a given TSE strain in a genetically similar non-transgenic 
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mouse strain, the incubation period has a small standard error and can be highly 
repeatable. However, the incubation period can be influenced by genetic factors in 
different mouse models (Bruce, BrMedBull 2003). Two alleles of the PrP gene have 
been identified in mice (denoted prnpa and prnpb) and represent the prion protein that is 
encoded by amino acids that differ at codons 108 and 189 (Westaway, Cell 1987). The 
incubation period in a prnpa versus a prnpb mouse can differ by hundreds of days and 
allows for the identification of different TSE strains (Bruce, BrMedBull 2003; Dickinson, 
Mol Gen Genet 1971; Bruce, J Gen Virol 1991; Dickinson, J Comp Pathol 1968).  
Transgenic mouse models that express the prion protein gene from many 
different species is an essential part of studying TSE disease. These transgenic mice do 
not express the mouse prion protein but instead are generated by knocking out the PrP 
or by insertion of the PRNP gene from a species of interest (Diack, Prog Mol Biol Transl 
Sci 2017). The first transgenic mouse over-expressed the hamster PRNP gene by 
random insertion into the murine genome (Scott, Cell 1989). Since then transgenic mice 
have been generated that express the bovine (TgBov XV; Buschmann and Groschup, J 
Infect Dis 2005), ovine (Tg338; Laude, C R Biologies 2002), cervid (Tg12; Kong, J 
Neurosci 2005), and human (Tg40; Kong, J Neurosci 2005) PRNP genes. These 
models have been used for the characterization of disease phenotypes (Thackray, J 
Gen Virol 2011). Transgenic mouse models also help with the understanding of the 
diversity of prion strains and their potential host range.  
Strain Variation 
 TSEs are known to have strain variations that can influence disease phenotype 
and susceptibility to disease, based on the genotype of the animal. Strains can differ in 
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incubation period, vacuolation profile, PrPSc accumulation, and PrPSc glycosylation 
profile (Solforosi, Prion 2013). Prion strain factors can be identified when the prion 
isolate is passed to a new host species (Wemheuer, Front. Aging Neurosci 2017). 
Strain variation first became apparent when sheep scrapie was: 1) transmitted to goats 
and 2) resulted in two different disease phenotypes (Pattison, J Comp Pathol 1961). 
Since then, mouse models have been used extensively to study strain variation. Strain 
typing can be done after disease characteristics have stabilized, which requires multiple 
passages of the agent in mice (Bruce, BrMedBull 1993). Stabilized strains in mice 
portray specific lesion profiles and PrPSc immunoreactivity patterns. Lesion profiles can 
differ in severity and the brain region that is affected, while PrPSc accumulation can 
target specific neurons, or differ in the type of accumulation (granular or aggregates) 
(Bruce, BrMedBull 2003). After stabilization and characterization, the strain is identified 
based on the incubation period, lesion profile, and PrPSc immunolabeling properties 
(Bruce, BrMedBull 2003).  
Interspecies Transmission 
 Interspecies transmission allows us to the study the potential host range for any 
TSE. Studying interspecies transmission is typically accomplished by experimental 
intracranial (IC) or oral inoculation. Intracranial inoculation can be used to determine if 
the agent has any potential to transmit disease to the new host species. However, to 
better characterize the disease pathogenesis the more natural, oral route can be used 
(Greenlee, ILAR 2015). The study of interspecies transmission has been accomplished 
using large animal as well as transgenic mouse models.  
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Sheep have been orally challenged with the bovine spongiform encephalopathy 
agent in lambs at 24 hours of age that produced high attack rates (7 out of 10 at a dose 
of 1.0 g) and at 2-3 weeks of age (12 out of 12 at a dose of 1.0 g; Hunter, J Virol 2012). 
Sheep have also been challenged with the BSE agent intracerebrally (Foster, Vet Rec 
1993) or intravenously (Houston, Lancet 2000). Sheep have also been challenged with 
the mule deer CWD agent by the intracranial route, and had a low attack rate (2 out of 
10, as discussed previously) (Hamir, J Vet Diagn Invest 2006). In addition, sheep have 
been challenged intracerebrally with the transmissible mink encephalopathy agent and 
had a low attack rate of (5 out of 20; Hadlow, Can J Vet Res 1987).  
Transgenic mouse models can also be used to study interspecies transmission. 
Mouse studies typically take significantly less time than large animal studies and are a 
good indication of whether a large animal study would be necessary. For example, the 
sheep scrapie isolate SSBP/1 in experimental studies, readily transmits to transgenic 
mice expressing the deer prion protein but does not produce disease in transgenic mice 
expressing the elk prion protein (Angers, PNAS 2014). Due to the findings in mice from 
this paper, the authors subsequently conducted an experiment by transmitting sheep 
scrapie to deer.  
References 
 
1. Prusiner SB. (1991). Molecular biology of prion diseases. Science, 252:1515-
1522 
 
2. Sigurdson, C. J., Nilsson, K. P. R., Hornemann, S., Manco, G., Polymenidou, M., 
Schwarz, P., ... & Aguzzi, A. (2007). Prion strain discrimination using luminescent 
conjugated polymers. Nature methods, 4(12), 1023. 
 
3. Prusiner SB. (1998). Prions. Proc. Natl. Acad. Sci, 95:13363-13383 
 
	 19	
4. Chandler RL, Turfrey BA. (1972). Inoculation of voles, Chinese hamsters, gerbils, 
and guinea-pigs with scrapie brain material. Res Vet Sci, 13(3):219-24 
 
5. Kimberlin RH, Marsh RF. (1975). Comparison of scrapie and transmissible mink 
encephalopathy in hamsters. I. Biochemical studies of brain during development 
of disease. J Infect Dis, 131(2):97-103 
 
6. Prusiner SB, Cochran SP, Baringer JR, Groth D, Masiarz F, McKinley M, 
Bildstein C, Garfin D, Hadlow WJ, Race RE, Eklund CM. (1980). Slow viruses: 
molecular properties of the agents causing scrapie in mice and hamsters. Prog 
Clin Biol Res, 39:73-89 
 
7. Prusiner SB, Groth DF, Cochran SP, McKinley MP, Masiarz FR. (1980). Gel 
electrophoresis and glass permeation chromatography of the hamster scrapie 
agent after enzymatic digestion and detergent extraction. Biochemistry, 
19(21):4892-8 
 
8. Prusiner SB, McKinley MP, Groth DF, Bowman KA, Mock NI, Cochran SP, 
Masiarz FR. (1981). Scrapie agent contains a hydrophobic protein. Proc Natl 
Acad Sci, 78(11):6675-9 
 
9. Bolton DC, McKinley MP, Prusiner SB. (1982) Identification of a protein that 
purifies with the scrapie prion. Science, 218(4579):1309-11 
 
10. Prusiner SB, Bolton DC, Groth DF, Bowman KA, Cochran SP, McKinley MP. 
(1982). Further purification and characterization of scrapie prions. Biochemistry, 
21(26):6942-50 
 
11.  Oesch B, Westaway D, Wälchli M, McKinley MP, Kent SBH, Aebersold R, Barry 
RA, Tempst P, Teplow DB, Hood LE, Prusiner SB, Weissmann C.(1985). A 
cellular gene encodes scrapie PrP 27-30 protein. Cell, 40:735-746 
 
12.  Basler K, Oesch B, Scott M, Westaway D, Wälchli M, Groth DF, McKinley MP, 
Prusiner SB, Weissmann C.(1986). Scrapie and cellular PrP isoforms are 
encoded by the same chromosomal gene. Cell, 46(3):417-28 
 
13.  Weissmann C, Flechsig E. (2003). PrP knock-out and PrP transgenic mice in 
prion research. Br Med Bull, 66:43-60 
 
14.  Büeler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ, Prusiner 
SB, Aguet M, Weissmann C. (1992). Normal development and behaviour of mice 
lacking the neuronal cell-surface PrP protein. Nature, 356(6370):577-82 
 
15.  Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. (1994). 
129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are 
developmentally normal. Mol Neurobiol, 8(2-3):121-7 
	 20	
 
16.  Jackson WS, Krost C, Borkowski AW, Kaczmarczyk L. (2014) Translation of the 
prion protein mRNA is robust in astrocytes but does not amplify during reactive 
astrocytosis in the mouse brain. PLoS One, 9:e95958  
 
17.  Nuvolone M, Hermann M, Sorce S, Russo G, Tiberi C, Schwarz P, Minikel E, 
Sanoudou D, Pelczar P, Aguzzi A. (2016) Strictly co-isogenic C57BL/6J-Prnp-/- 
mice: a rigorous resource for prion science. J Exp Med, 213: 313-327 
 
18.  Watts, J. C., Bourkas, M. E., & Arshad, H. (2017). The function of the cellular 
prion protein in health and disease. Acta neuropathologica, 1-20 
 
19.  Bremer, J., Baumann, F., Tiberi, C., Wessig, C., Fischer, H., Schwarz, P., ... & 
Aguzzi, A. (2010). Axonal prion protein is required for peripheral myelin 
maintenance. Nature neuroscience, 13(3), 310 
 
20.  Nishida, N., Tremblay, P., Sugimoto, T., Shigematsu, K., Shirabe, S., Petromilli, 
C., ... & Torchia, M. (1999). A mouse prion protein transgene rescues mice 
deficient for the prion protein gene from purkinje cell degeneration and 
demyelination. Laboratory investigation; a journal of technical methods and 
pathology, 79(6), 689-697. 
 
21.  Diarra-Mehrpour, M., Arrabal, S., Jalil, A., Pinson, X., Gaudin, C., Piétu, G., ... & 
Chouaib, S. (2004). Prion protein prevents human breast carcinoma cell line from 
tumor necrosis factor α-induced cell death. Cancer research, 64(2), 719-727. 
 
22.  Bounhar, Y., Zhang, Y., Goodyer, C. G., & LeBlanc, A. (2001). Prion protein 
protects human neurons against Bax-mediated apoptosis. Journal of Biological 
Chemistry, 276(42), 39145-39149. 
 
23.  Kim, B. H., Lee, H. G., Choi, J. K., Kim, J. I., Choi, E. K., Carp, R. I., & Kim, Y. S. 
(2004). The cellular prion protein (PrPC) prevents apoptotic neuronal cell death 
and mitochondrial dysfunction induced by serum deprivation. Molecular brain 
research, 124(1), 40-50. 
 
24.  Kuwahara, C., Takeuchi, A. M., Nishimura, T., Haraguchi, K., Kubosaki, A., 
Matsumoto, Y., ... & Onodera, T. (1999). Prions prevent neuronal cell-line death. 
Nature, 400(6741), 225. 
 
25.  Roucou, X., Giannopoulos, P. N., Zhang, Y., Jodoin, J., Goodyer, C. G., & 
LeBlanc, A. (2005). Cellular prion protein inhibits proapoptotic Bax 
conformational change in human neurons and in breast carcinoma MCF-7 cells. 
Cell death and differentiation, 12(7), 783. 
 
	 21	
26.  Yu, G., Jiang, L., Xu, Y., Guo, H., Liu, H., Zhang, Y., ... & Ma, J. (2012). 
Silencing prion protein in MDA-MB-435 breast cancer cells leads to pleiotropic 
cellular responses to cytotoxic stimuli. PloS one, 7(11), e48146. 
 
27.  Moreno, J. A., & Telling, G. C. (2017). Insights into Mechanisms of Transmission 
and Pathogenesis from Transgenic Mouse Models of Prion Diseases. In Prions 
(pp. 219-252). Humana Press, New York, NY. 
 
28.  Büeler, H., Aguzzi, A., Sailer, A., Greiner, R. A., Autenried, P., Aguet, M., & 
Weissmann, C. (1993). Mice devoid of PrP are resistant to scrapie. Cell, 73(7), 
1339-1347. 
 
29.  Prusiner, S. B., Groth, D., Serban, A., Koehler, R., Foster, D., Torchia, M., ... & 
DeArmond, S. J. (1993). Ablation of the prion protein (PrP) gene in mice prevents 
scrapie and facilitates production of anti-PrP antibodies. Proceedings of the 
National Academy of Sciences, 90(22), 10608-10612. 
 
30.  Sailer, A., Büeler, H., Fischer, M., Aguzzi, A., & Weissmann, C. (1994). No 
propagation of prions in mice devoid of PrP. Cell, 77(7), 967-968. 
 
31.  Büeler, H., Raeber, A., Sailer, A., Fischer, M., Aguzzi, A., & Weissmann, C. 
(1994). High prion and PrPSc levels but delayed onset of disease in scrapie-
inoculated mice heterozygous for a disrupted PrP gene. Molecular Medicine, 
1(1), 19. 
 
32.  Sandberg, M. K., Al-Doujaily, H., Sharps, B., Clarke, A. R., & Collinge, J. (2011). 
Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. 
Nature, 470(7335), 540. 
 
33.  Sandberg, M. K., Al-Doujaily, H., Sharps, B., De Oliveira, M. W., Schmidt, C., 
Richard-Londt, A., ... & Clarke, A. R. (2014). Prion neuropathology follows the 
accumulation of alternate prion protein isoforms after infective titre has peaked. 
Nature communications, 5, 4347. 
 
34.  Geschwind MD., (2015). Prion Diseases. Continuum (Minneap Minn), 21 (6 
Neuroinfectious Disease): 1612-38. 
 
35.  Kobayashi, A., Iwasaki, Y., Otsuka, H., Yamada, M., Yoshida, M., Matsuura, Y., 
... & Kitamoto, T. (2013). Deciphering the pathogenesis of sporadic Creutzfeldt-
Jakob disease with codon 129 M/V and type 2 abnormal prion protein. Acta 
neuropathologica communications, 1(1), 74. 
 
36.  Ironside, J. W. (2012). Variant Creutzfeldt-Jakob disease: an update. Folia 
neuropathologica, 50(1), 50-56. 
 
	 22	
37.  Lee, S. M., Chung, M., Hwang, K. J., Ju, Y. R., Hyeon, J. W., Park, J. S., ... & 
Kim, S. Y. (2014). Biological network inferences for a protection mechanism 
against familial Creutzfeldt-Jakob disease with E200K pathogenic mutation. BMC 
medical genomics, 7(1), 52. 
 
38.  Wells, G. A., Scott, A. C., Johnson, C. T., Gunning, R. F., Hancock, R. D., 
Jeffrey, M., ... & Bradley, R. (1987). A novel progressive spongiform 
encephalopathy in cattle. Veterinary Record, 121(18), 419-420. 
 
39.  Williams ES. (2005). Chronic wasting disease, Vet Pathol, 42, 430-549. 
 
40.  Cuille, J., & Chelle, P. L. (1938). Investigations of scrapie in sheep. Vet Med, 34, 
417-418. 
 
41.  Fast C, Groschup MH. (2013). Classical and atypical scrapie in sheep and 
goats. In: Zou W-Q, Gambetti P, eds. Prions and Diseases: 2, Animals, Humans, 
and Environment. New York: Springer Science + Business Media. 
 
42.  Eckroade, R. J., Zurhein, G. M., & Hanson, R. P. (1973). Transmissible mink 
encephalopathy in carnivores: clinical, light and electron microscopic studies in 
raccons, skunks and ferrets. Journal of wildlife diseases, 9(3), 229-240. 
 
43.  Hagiwara, K. I., Hara, H., & Hanada, K. (2013). Species-barrier phenomenon in 
prion transmissibility from a viewpoint of protein science. The Journal of 
Biochemistry, 153(2), 139-145. 
 
44.  Sigurdson, C. J., Nilsson, K. P. R., Hornemann, S., Manco, G., Fernández-
Borges, N., Schwarz, P., ... & Aguzzi, A. (2010). A molecular switch controls 
interspecies prion disease transmission in mice. The Journal of clinical 
investigation, 120(7), 2590-2599. 
 
45.  Bett, C., Fernández-Borges, N., Kurt, T. D., Lucero, M., Nilsson, K. P. R., 
Castilla, J., & Sigurdson, C. J. (2012). Structure of the β2-α2 loop and 
interspecies prion transmission. The FASEB Journal, 26(7), 2868-2876. 
 
46.  Lloyd, S., Mead, S., & Collinge, J. (2011). Genetics of prion disease. In Prion 
Proteins (pp. 1-22). Springer, Berlin, Heidelberg. 
 
47.  Bruce, M. E. (1993). Scrapie strain variation and mutation. British medical 
bulletin, 49(4), 822-838. 
 
48.  Moore, S. J., Smith, J. D., Greenlee, M. W., Nicholson, E. M., Richt, J. A., & 
Greenlee, J. J. (2016). Comparison of two US sheep scrapie isolates supports 
identification as separate strains. Veterinary pathology, 53(6), 1187-1196. 
 
	 23	
49.  Bruce, M. E. (2003). TSE strain variation: an investigation into prion disease 
diversity. British medical bulletin, 66(1), 99-108. 
 
50.  Morales, R., Abid, K., & Soto, C. (2007). The prion strain phenomenon: 
molecular basis and unprecedented features. Biochimica et Biophysica Acta 
(BBA)-Molecular Basis of Disease, 1772(6), 681-691. 
 
51.  Westaway, D., Goodman, P. A., Mirenda, C. A., McKinley, M. P., Carlson, G. A., 
& Prusiner, S. B. (1987). Distinct prion proteins in short and long scrapie 
incubation period mice. Cell, 51(4), 651-662. 
 
52.  Bruce, M. E., Boyle, A., & McConnell, I. (2004). TSE strain typing in mice. In 
Techniques in prion research (pp. 132-146). Birkhäuser, Basel. 
 
53.  Gonzalez, L., Sisó, S., Monleon, E., Casalone, C., van Keulen, L. J., Balkema-
Buschmann, A., ... & Badiola, J. J. (2010). Variability in disease phenotypes 
within a single PRNP genotype suggests the existence of multiple natural sheep 
scrapie strains within Europe. Journal of General Virology, 91(10), 2630-2641. 
 
54.  Ligios, C., Jeffrey, M., Ryder, S. J., Bellworthy, S. J., & Simmons, M. M. (2002). 
Distinction of scrapie phenotypes in sheep by lesion profiling. Journal of 
Comparative Pathology, 127(1), 45-57. 
 
55.  Spiropoulos, J., Casalone, C., Caramelli, M., & Simmons, M. M. (2007). 
Immunohistochemistry for PrPSc in natural scrapie reveals patterns which are 
associated with the PrP genotype. Neuropathology and applied neurobiology, 
33(4), 398-409. 
 
56.  Jeffrey, M., González, L., Espenes, A., Press, C., Martin, S., Chaplin, M., ... & 
McGovern, G. (2006). Transportation of prion protein across the intestinal 
mucosa of scrapie‐susceptible and scrapie‐resistant sheep. The Journal of 
pathology, 209(1), 4-14. 
 
57.  Spraker, T. R., VerCauteren, K. C., Gidlewski, T., Schneider, D. A., Munger, R., 
Balachandran, A., & O'Rourke, K. I. (2009). Antemortem detection of PrPCWD in 
preclinical, ranch-raised rocky mountain Elk (Cevvus Elaphus Nelsoni) by biopsy 
of the rectal mucosa. Journal of veterinary diagnostic investigation, 21(1), 15-24. 
 
58.  Corda, E., Beck, K. E., Sallis, R. E., Vickery, C. M., Denyer, M., Webb, P. R., ... 
& Spiropoulos, J. (2012). The interpretation of disease phenotypes to identify 
TSE strains in mice: characterisation of BSE using PrP Sc distribution patterns in 
the brain. Veterinary research, 43(1), 86. 
 
59.  Bencsik, A., & Baron, T. (2011). Histopathological studies of “CH1641-like” 
scrapie sources versus classical scrapie and BSE transmitted to ovine transgenic 
mice (TgOvPrP4). PloS one, 6(7), e22105. 
	 24	
 
60.  Konold, T., Lee, Y. H., Stack, M. J., Horrocks, C., Green, R. B., Chaplin, M., ... & 
Wilesmith, J. W. (2006). Different prion disease phenotypes result from 
inoculation of cattle with two temporally separated sources of sheep scrapie from 
Great Britain. BMC Veterinary Research, 2(1), 31. 
 
61.  Piro, J. R., Harris, B. T., Nishina, K., Soto, C., Morales, R., Rees, J. R., & 
Supattapone, S. (2009). Prion protein glycosylation is not required for strain-
specific neurotropism. Journal of virology, 83(11), 5321-5328. 
 
62.  Endo, T., Groth, D., Prusiner, S. B., & Kobata, A. (1989). Diversity of 
oligosaccharide structures linked to asparagines of the scrapie prion protein. 
Biochemistry, 28(21), 8380-8388. 
 
63.  Locht, C., Chesebro, B., Race, R., & Keith, J. M. (1986). Molecular cloning and 
complete sequence of prion protein cDNA from mouse brain infected with the 
scrapie agent. Proceedings of the National Academy of Sciences, 83(17), 6372-
6376. 
 
64.  Martin, S., Jeffrey, M., González, L., Sisó, S., Reid, H. W., Steele, P., ... & 
Balachandran, A. (2009). Immunohistochemical and biochemical characteristics 
of BSE and CWD in experimentally infected European red deer (Cervus elaphus 
elaphus). BMC veterinary research, 5(1), 26. 
 
65.  Greenlee, J. J., & Greenlee, M. H. W. (2015). The transmissible spongiform 
encephalopathies of livestock. ILAR journal, 56(1), 7-25. 
 
66.  Biacabe, A. G., Laplanche, J. L., Ryder, S., & Baron, T. (2004). Distinct 
molecular phenotypes in bovine prion diseases. EMBO reports, 5(1), 110-115. 
 
67.  Biacabe, A. G., Jacobs, J. G., Bencsik, A., Langeveld, J. P., & Baron, T. G. 
(2007). H-type bovine spongiform encephalopathy: complex molecular features 
and similarities with human prion diseases. Prion, 1(1), 61-68. 
 
68.  Balkema-Buschmann, A., Ziegler, U., McIntyre, L., Keller, M., Hoffmann, C., 
Rogers, R., ... & Groschup, M. H. (2011). Experimental challenge of cattle with 
German atypical bovine spongiform encephalopathy (BSE) isolates. Journal of 
Toxicology and Environmental Health, Part A, 74(2-4), 103-109. 
 
69.  Konold, T., Bone, G. E., Clifford, D., Chaplin, M. J., Cawthraw, S., Stack, M. J., 
& Simmons, M. M. (2012). Experimental H-type and L-type bovine spongiform 
encephalopathy in cattle: observation of two clinical syndromes and diagnostic 
challenges. BMC veterinary research, 8(1), 22. 
 
	 25	
70.  IDEXX. Bovine Spongiform Encephalopathy-Scrapie Antigen Test Kit, EIA. 
IDEXX Laboratories. 2017. https://bmcvetres.biomedcentral.com/submission-
guidelines/preparing-your-manuscript/research-article. Assessed 03 March 2018. 
 
71.  Bio-Rad's Second Generation CWD Test Approved By USDA. (2003, July 15). 
Retrieved March 03, 2018, from http://cwd-info.org/bio-rads-second-generation-
cwd-test-approved-by-usda/ 
 
72.  Hibler, C. P., Wilson, K. L., Spraker, T. R., Miller, M. W., Zink, R. R., DeBuse, L. 
L., ... & Smeltzer, J. F. (2003). Field validation and assessment of an enzyme-
linked immunosorbent assay for detecting chronic wasting disease in mule deer 
(Odocoileus hemionus), white-tailed deer (Odocoileus virginianus), and Rocky 
Mountain elk (Cervus elaphus nelsoni). Journal of Veterinary Diagnostic 
Investigation, 15(4), 311-319. 
 
73.  Kittelberger, R., et al. “Evaluation of two commercial, rapid, ELISA kits testing for 
scrapie in retro-pharyngeal lymph nodes in sheep.” New Zealand veterinary 
journal, 62(6), 343-350. 
 
74.  Smith, J. D., & Greenlee, J. J. (2014). Detection of misfolded prion protein in 
retina samples of sheep and cattle by use of a commercially available enzyme 
immunoassay. American journal of veterinary research, 75(3), 268-272. 
 
75.  Begara-McGorum, I., Gonzalez, L., Simmons, M., Hunter, N., Houston, F., & 
Jeffrey, M. (2002). Vacuolar lesion profile in sheep scrapie: factors influencing its 
variation and relationship to disease-specific PrP accumulation. Journal of 
comparative pathology, 127(1), 59-68. 
 
76.  Gonzalez, L., Martin, S., Begara-McGorum, I., Hunter, N., Houston, F., 
Simmons, M., & Jeffrey, M. (2002). Effects of agent strain and host genotype on 
PrP accumulation in the brain of sheep naturally and experimentally affected with 
scrapie. Journal of comparative pathology, 126(1), 17-29. 
 
77.  Simmons, M. M., Harris, P., Jeffrey, M., Meek, S. C., Blamire, W. H., & Wells, G. 
A. H. (1996). Samples of clinically suspect cases. The Veterinary Record, 138, 
175-177. 
 
78.  Jeffrey, M., McGovern, G., Sisó, S., & González, L. (2011). Cellular and sub-
cellular pathology of animal prion diseases: relationship between morphological 
changes, accumulation of abnormal prion protein and clinical disease. Acta 
neuropathologica, 121(1), 113-134. 
 
79.  Imran, M., & Mahmood, S. (2011). An overview of animal prion diseases. 
Virology journal, 8(1), 493. 
 
	 26	
80.  Plummer, P. J. G. (1946). Scrapie—a disease of sheep: a review of the 
literature. Canadian journal of comparative medicine and veterinary science, 
10(2), 49. 
 
81.  Brown, P., & Bradley, R. (1998). 1755 and all that: a historical primer of 
transmissible spongiform encephalopathy. BMJ: British Medical Journal, 
317(7174), 1688. 
 
82.  Baylis, M., & Goldmann, W. (2004). The genetics of scrapie in sheep and goats. 
Current molecular medicine, 4(4), 385-396. 
 
83.  Goldmann, W., Hunter, N., Smith, G., Foster, J., & Hope, J. (1994). PrP 
genotype and agent effects in scrapie: change in allelic interaction with different 
isolates of agent in sheep, a natural host of scrapie. Journal of General Virology, 
75(5), 989-995. 
 
84. Cutlip, R. C., Miller, J. M., Race, R. E., Jenny, A. L., Katz, J. B., Lehmkuhl, H. D., 
... & Robinson, M. M. (1994). Intracerebral transmission of scrapie to 
cattle. Journal of Infectious Diseases, 169(4), 814-820. 
 
85.  Hamir, A. N., Kehrli Jr, M. E., Kunkle, R. A., Greenlee, J. J., Nicholson, E. M., 
Richt, J. A., ... & Cutlip, R. C. (2011). Experimental interspecies transmission 
studies of the transmissible spongiform encephalopathies to cattle: comparison 
to bovine spongiform encephalopathy in cattle. Journal of Veterinary Diagnostic 
Investigation, 23(3), 407-420. 
 
86.  Greenlee, J. J., Smith, J. D., & Kunkle, R. A. (2011). White-tailed deer are 
susceptible to the agent of sheep scrapie by intracerebral inoculation. Veterinary 
research, 42(1), 107. 
 
87.  Hamir, A. N., Miller, J. M., Cutlip, R. C., Kunkle, R. A., Jenny, A. L., Stack, M. J., 
... & Richt, J. A. (2004). Transmission of sheep scrapie to elk (Cervus elaphus 
nelsoni) by intracerebral inoculation: final outcome of the experiment. Journal of 
Veterinary Diagnostic Investigation, 16(4), 316-321. 
 
88.  Hamir, A., Miller, J., Cutlip, R., Stack, M., Chaplin, M., Jenny, A., & Williams, E. 
(2003). Experimental inoculation of scrapie and chronic wasting disease agents 
in raccoons (Procyon lotor). Veterinary record, 153, 121-123. 
 
89.  Greenlee, J. J., Kunkle, R. A., Smith, J. D., & Greenlee, M. H. W. (2016). 
Scrapie in swine: a diagnostic challenge. Food Safety, 4(4), 110-114. 
 
90.  Chandler, R.L. (1961). Encephalopathy in mice produced by inoculation with 
scrapie brain material. Lanclet, 1(7191), 1378-9. 
 
	 27	
91.  Bruce, M. E., McBride, P. A., Jeffrey, M., & Scott, J. R. (1994). PrP in pathology 
and pathogenesis in scrapie-infected mice. Molecular neurobiology, 8(2-3), 105-
112. 
 
92.  Beck, K. E., Vickery, C. M., Lockey, R., Holder, T., Thorne, L., Terry, L. A., ... & 
Spiropoulos, J. (2012). The interpretation of disease phenotypes to identify TSE 
strains following murine bioassay: characterisation of classical scrapie. 
Veterinary research, 43(1), 77. 
 
93.  Hamir, A. N., Kunkle, R. A., Richt, J. A., Miller, J. M., Cutlip, R. C., & Jenny, A. L. 
(2005). Experimental transmission of sheep scrapie by intracerebral and oral 
routes to genetically susceptible Suffolk sheep in the United States. Journal of 
veterinary diagnostic investigation, 17(1), 3-9. 
 
94. Hamir, A. N., Kunkle, R. A., Richt, J. A., Greenlee, J. J., & Miller, J. M. (2009).   
Serial passage of sheep scrapie inoculum in Suffolk sheep. Veterinary pathology, 
46(1), 39-44. 
 
95. Hamir, A. N., Kunkle, R. A., Richt, J. A., Miller, J. M., & Greenlee, J. J. (2008). 
Experimental transmission of US scrapie agent by nasal, peritoneal, and 
conjunctival routes to genetically susceptible sheep. Veterinary pathology, 45(1), 7-
11. 
 
96. Bulgin, M. S., Sorensen, S. J., & Matlock, M. E. (2006). Association between 
incubation time and genotype in sheep experimentally inoculated with scrapie-
positive brain homogenate. American journal of veterinary research, 67(3), 498-
504. 
 
97. Hamir, A. N., Richt, J. A., Kunkle, R. A., Greenlee, J. J., Bulgin, M. S., Gregori, L., 
& Rohwer, R. G. (2009). Characterization of a US sheep scrapie isolate with short 
incubation time. Veterinary pathology, 46(6), 1205-1212. 
 
98. Hunter, N. (2003). Scrapie and experimental BSE in sheep. British Medical 
Bulletin, 66(1), 171-183. 
 
99. Houston, E. F., Halliday, S. I., Jeffrey, M., Goldmann, W., & Hunter, N. (2002). 
New Zealand sheep with scrapie-susceptible PrP genotypes succumb to 
experimental challenge with a sheep-passaged scrapie isolate (SSBP/1). Journal 
of General Virology, 83(5), 1247-1250. 
 
100. Goldmann, W., Hunter, N., Benson, G., Foster, J. D., & Hope, J. (1991). Different 
scrapie-associated fibril proteins (PrP) are encoded by lines of sheep selected for 
different alleles of the Sip gene. Journal of General Virology, 72(10), 2411-2417. 
 
101. Houston, F., Goldmann, W., Foster, J., González, L., Jeffrey, M., & Hunter, N. 
(2015). Comparative susceptibility of sheep of different origins, breeds and PRNP 
	 28	
genotypes to challenge with bovine spongiform encephalopathy and scrapie. PLoS 
One, 10(11), e0143251. 
 
102. Gossner, A., Roupaka, S., Foster, J., Hunter, N., & Hopkins, J. (2011). 
Transcriptional profiling of peripheral lymphoid tissue reveals genes and networks 
linked to SSBP/1 scrapie pathology in sheep. Veterinary microbiology, 153(3-4), 
218-228. 
 
103. Benestad, S. L., Sarradin, P., Thu, B., Schönheit, J., Tranulis, M. A., & Bratberg, 
B. (2003). Cases of scrapie with unusual features in Norway and designation of a 
new type, Nor98. The Veterinary Record, 153(7), 202-208. 
 
104. Benestad, S. L., Arsac, J. N., Goldmann, W., & Nöremark, M. (2008). 
Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology. 
Veterinary research, 39(4), 1-14. 
 
105. Hayashi, H. K., Yokoyama, T., Takata, M., Iwamaru, Y., Imamura, M., Ushiki, Y. 
K., & Shinagawa, M. (2005). The N-terminal cleavage site of PrPSc from BSE 
differs from that of PrPSc from scrapie. Biochemical and biophysical research 
communications, 328(4), 1024-1027. 
 
106. Hope, J., Wood, S. C., Birkett, C. R., Chong, A., Bruce, M. E., Cairns, D., ... & 
Bostock, C. J. (1999). Molecular analysis of ovine prion protein identifies 
similarities between BSE and an experimental isolate of natural scrapie, CH1641. 
Journal of General Virology, 80(1), 1-4. 
 
107. Somerville, R. A., & Ritchie, L. A. (1990). Differential glycosylation of the protein 
(PrP) forming scrapie-associated fibrils. Journal of general virology, 71(4), 833-
839. 
 
108. Andréoletti, O., Orge, L., Benestad, S. L., Beringue, V., Litaise, C., Simon, S., ... 
& Corbière, F. (2011). Atypical/Nor98 scrapie infectivity in sheep peripheral 
tissues. PLoS pathogens, 7(2), e1001285. 
 
109. Haley, N. J., & Hoover, E. A. (2015). Chronic wasting disease of cervids: current 
knowledge and future perspectives. Annu. Rev. Anim. Biosci., 3(1), 305-325. 
 
110. Gilch, S., Chitoor, N., Taguchi, Y., Stuart, M., Jewell, J. E., & Schätzl, H. M. 
(2011). Chronic wasting disease. In Prion Proteins (pp. 51-77). Springer, Berlin, 
Heidelberg. 
 
111. Williams, E. S. (2005). Chronic wasting disease. Veterinary pathology, 42(5), 
530-549. 
 
	 29	
112. Moore, S. J., Kunkle, R., Greenlee, M. H. W., Nicholson, E., Richt, J., Hamir, A., 
... & Greenlee, J. (2016). Horizontal transmission of chronic wasting disease in 
reindeer. Emerging infectious diseases, 22(12), 2142. 
 
113. Saunders, S. E., Bartelt-Hunt, S. L., & Bartz, J. C. (2012). Occurrence, 
transmission, and zoonotic potential of chronic wasting disease. Emerging 
infectious diseases, 18(3), 369. 
 
114. Mathiason, C. K., Powers, J. G., Dahmes, S. J., Osborn, D. A., Miller, K. V., 
Warren, R. J., ... & Wild, M. A. (2006). Infectious prions in the saliva and blood of 
deer with chronic wasting disease. science, 314(5796), 133-136. 
 
115. Miller, M. W., Williams, E. S., Hobbs, N. T., & Wolfe, L. L. (2004). Environmental 
sources of prion transmission in mule deer. Emerging infectious diseases, 10(6), 
1003. 
 
116. Mathiason, C. K., Hays, S. A., Powers, J., Hayes-Klug, J., Langenberg, J., 
Dahmes, S. J., ... & Hoover, E. A. (2009). Infectious prions in pre-clinical deer and 
transmission of chronic wasting disease solely by environmental exposure. PLoS 
One, 4(6), e5916. 
 
117. Sigurdson, C. J. (2008). A prion disease of cervids: chronic wasting disease. 
Veterinary research, 39(4), 1-12. 
 
118. Kong, Q., Huang, S., Zou, W., Vanegas, D., Wang, M., Wu, D., ... & Chen, K. 
(2005). Chronic wasting disease of elk: transmissibility to humans examined by 
transgenic mouse models. Journal of Neuroscience, 25(35), 7944-7949. 
 
119. Hamir, A. N., Kunkle, R. A., Cutlip, R. C., Miller, J. M., Williams, E. S., & Richt, J. 
A. (2006). Transmission of chronic wasting disease of mule deer to Suffolk sheep 
following intracerebral inoculation. Journal of veterinary diagnostic investigation, 
18(6), 558-565. 
 
120. Madsen-Bouterse, S. A., Schneider, D. A., Zhuang, D., Dassanayake, R. P., 
Balachandran, A., Mitchell, G. B., & O'Rourke, K. I. (2016). Primary transmission of 
chronic wasting disease versus scrapie prions from small ruminants to transgenic 
mice expressing ovine or cervid prion protein. Journal of General Virology, 97(9), 
2451-2460. 
 
121. Chandler, R. L. (1963). Experimental scrapie in the mouse. Res Vet Sci, 4, 276-
285. 
 
122. Dickinson, A. G., & Meikle, V. M. (1971). Host-genotype and agent effects in 
scrapie incubation: change in allelic interaction with different strains of agent. 
Molecular and General Genetics MGG, 112(1), 73-79. 
 
	 30	
123. Bruce, M. E., McConnell, I., Fraser, H., & Dickinson, A. G. (1991). The disease 
characteristics of different strains of scrapie in Sinc congenic mouse lines: 
implications for the nature of the agent and host control of pathogenesis. Journal of 
General Virology, 72(3), 595-603. 
 
124. Dickinson, A. G., Meikle, V. M., & Fraser, H. (1968). Identification of a gene 
which controls the incubation period of some strains of scrapie agent in mice. 
Journal of comparative pathology, 78(3), 293-299. 
 
125. Diack, A. B., Alibhai, J. D., & Manson, J. C. (2017). Gene Targeted Transgenic 
Mouse Models in Prion Research. In Progress in molecular biology and 
translational science (Vol. 150, pp. 157-179). Academic Press. 
 
126. Scott, M., Foster, D., Mirenda, C., Serban, D., Coufal, F., Wälchli, M., ... & 
Westaway, D. (1989). Transgenic mice expressing hamster prion protein produce 
species-specific scrapie infectivity and amyloid plaques. Cell, 59(5), 847-857. 
 
127. Buschmann, A., & Groschup, M. H. (2005). Highly bovine spongiform 
encephalopathy–sensitive transgenic mice confirm the essential restriction of 
infectivity to the nervous system in clinically diseased cattle. The Journal of 
infectious diseases, 192(5), 934-942. 
 
128. Laude, H., Vilette, D., Le Dur, A., Archer, F., Soulier, S., Besnard, N., ... & Vilotte, 
J. L. (2002). New in vivo and ex vivo models for the experimental study of sheep 
scrapie: development and perspectives. Comptes rendus biologies, 325(1), 49-57. 
 
129. Kong, Q., Huang, S., Zou, W., Vanegas, D., Wang, M., Wu, D., ... & Chen, K. 
(2005). Chronic wasting disease of elk: transmissibility to humans examined by 
transgenic mouse models. Journal of Neuroscience, 25(35), 7944-7949. 
 
130. Thackray, A. M., Hopkins, L., Lockey, R., Spiropoulos, J., & Bujdoso, R. (2011). 
Emergence of multiple prion strains from single isolates of ovine scrapie. Journal of 
General Virology, 92(6), 1482-1491. 
 
131. Wemheuer, W. M., Wrede, A., & Schulz-Schaeffer, W. J. (2017). Types and 
strains: their essential role in understanding protein aggregation in 
neurodegenerative diseases. Frontiers in aging neuroscience, 9, 187. 
 
132. Solforosi, L., Milani, M., Mancini, N., Clementi, M., & Burioni, R. (2013). A closer 
look at prion strains: characterization and important implications. Prion, 7(2), 99-
108. 
 
133. Pattison, I.H., Millson, G.C. (1961). Scrapie produced experimentally in goats 
with special reference to the clinical syndrome. J Comp Pathol, 71, 101-109 
 
	 31	
134. Hunter, N., Houston, F., Foster, J., Goldmann, W., Drummond, D., Parnham, D., 
... & Chong, A. (2012). Susceptibility of young sheep to oral infection with bovine 
spongiform encephalopathy decreases significantly after weaning. Journal of 
virology, 86(21), 11856-11862. 
 
135. Foster, J. D., Hope, J., & Fraser, H. (1993). Transmission of bovine spongiform 
encephalopathy to sheep and goats. The Veterinary Record, 133(14), 339-341. 
 
136. Houston, F., Foster, J. D., Chong, A., Hunter, N., & Bostock, C. J. (2000). 
Transmission of BSE by blood transfusion in sheep. The Lancet, 356(9234), 999-
1000. 
 
137. Hadlow, W. J., Race, R. E., & Kennedy, R. C. (1987). Experimental infection of 
sheep and goats with transmissible mink encephalopathy virus. Canadian Journal 
of Veterinary Research, 51(1), 135. 
 
138. Angers, R., Christiansen, J., Nalls, A. V., Kang, H. E., Hunter, N., Hoover, E., ... 
& Telling, G. C. (2014). Structural effects of PrP polymorphisms on intra-and 
interspecies prion transmission. Proceedings of the National Academy of Sciences, 
111(30), 11169-11174. 
 
 
  
	 32	
CHAPTER 2. DISEASE PHENOTYPE OF SCRAPIE IN SHEEP IS CHANGED UPON 
EXPERIMENTAL PASSAGE THROUGH WHITE-TAILED DEER 
 
A paper in preparation for Veterinary Research 
Robyn Kokemuller1, S. Jo Moore1, M. Heather West Greenlee2, Justin Greenlee1 
1 Virus and Prion Research Unit, National Animal Disease Center, USDA, ARS, Ames, IA  
2 Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA  
 
Abstract 
Transmissible spongiform encephalopathy (TSE) agents have strain variations 
that influence disease phenotype and may affect the potential for interspecies 
transmission. Since deer and sheep may use the same grazing land, it is important to 
understand the potential for transmission of TSEs between these species. A US scrapie 
isolate (No.13-7) had a 100% attack rate in white-tailed deer (WTD) after oronasal 
challenge. The purpose of this study was to determine if sheep are susceptible to 
oronasal challenge with the scrapie agent from WTD. Suffolk lambs of various PRNP 
genotypes were challenged by the oronasal route with a 10% brain homogenate from 
scrapie-affected WTD. Upon development of clinical signs, sheep were euthanized and 
necropsied. Tissues were tested for PrPSc by enzyme immunoassay (EIA), western blot 
(WB), and immunohistochemistry (IHC). The first sheep to develop clinical signs at 
approximately 29 months post-inoculation (MPI) had the VRQ/VRQ genotype. One of 
the two sheep of the ARQ/ARQ genotype also developed clinical signs at 48 MPI. This 
is in contrast to the original No.13-7 inoculum that has a faster incubation period in 
sheep with the ARQ/ARQ genotype (20 MPI). A more rapid incubation period in VV136 
rather than AA136 sheep indicates a phenotype change and potentially the generation 
of new scrapie strain properties. This work raises the potential concern that scrapie 
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infected deer could serve as a confounding factor to scrapie eradication programs as 
scrapie from deer is transmissible to sheep by the oronasal route.  
Introduction 
Transmissible spongiform encephalopathies (TSEs) or prion diseases are 
neurodegenerative diseases that are the result of misfolding of the prion protein from 
the normal cellular form (PrPC) to the disease-associated form (PrPSc) [1].  TSE’s affect 
sheep (scrapie), deer (chronic wasting disease; CWD), cattle (bovine spongiform 
encephalopathy), and humans (eg. Creutzfeldt-Jakob disease). TSEs can be identified 
and differentiated by characterizing the PrPSc accumulation in various brain regions 
using immunohistochemistry, western blot, or bioassay in transgenic mouse models. 
There are strain variations between TSE agents that influence disease phenotype (e.g. 
incubation time, location of PrPSc deposition, etc.) and may affect susceptibility of 
animals with different prion protein gene (PRNP) sequences [2]. 
Susceptibility of sheep to the scrapie agent is associated with polymorphisms in 
PRNP at 3 codons: 136 valine (V), 154 arginine (R), and 171 glutamine (Q) (VRQ). The 
strongest resistance of sheep to scrapie is associated with codons 136 alanine (A), 154 
arginine (R), and 171 arginine (R) (ARR haplotype) [3]. The most influential codon being 
171, where QQ171 sheep are susceptible and RR171 sheep are resistant [4]. Disease 
phenotype can be influenced by genotype of the sheep donor, and the species or tissue 
from which the TSE is derived [5, 6].  
Since it is possible for sheep and deer to share the same grazing lands, it is 
important to understand the potential for interspecies transmission of the scrapie and 
CWD agents. Suffolk sheep intracranially inoculated with the CWD agent from white-
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tailed deer had an attack rate of 26.66% (4 out of 15) (unpublished). To date, attempts 
to oronasally transmit CWD to sheep has been unsuccessful (study currently at 50 
MPI).  However, white-tailed deer had a 100% attack rate when intracranially or 
oronasally inoculated with a US scrapie isolate (No.13-7) [7; Greenlee submitted]. The 
purpose of this study was to determine the susceptibility of sheep to oronasal challenge 
with the scrapie agent derived from inoculum made from white-tailed deer cerebrum or 
brainstem at the level of the obex. 
Methods and Materials 
All animal experiments described were reviewed and approved by the National Animal 
Disease Center’s Institutional Animal Care and Use Committee (protocol number 2777 
[sheep] and 2730 [mouse bioassay]) and were carried out in strict accordance with the 
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 
Resources, National Academy of Sciences, Washington DC) and the Guide for the Care 
and Use of Agricultural Animals in Research and Teaching (Federation of Animal 
Science Societies, Champaign, IL).  
Suffolk lambs from the National Animal Disease Center’s (NADC) scrapie-free 
flock of PRNP genotype VV136RR154QQ171 (VV136) (n=4), AV136RR154QR171 (n=2), and 
AA136RR154QQ171 (AA136) (n=4) were challenged by the oronasal route at 
approximately 5 months of age with a 10% brain homogenate from No.13-7 scrapie-
affected WTD cerebrum (n=5) or brainstem at the level of the obex (n=5). Sheep were 
observed daily throughout the duration of the experiment. Clinical signs included: poor 
body coordination, slow to rise, biting in the flank area, weight loss, and hunched 
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posture. Upon development of intercurrent disease or neurologic signs consistent with 
TSE, or at the end of the experiment, sheep were euthanized and necropsied.  
 The inocula were composed of brain homogenate from a white-tailed deer (#22) 
that was challenged oronasally with the scrapie isolate No.13-7 (Greenlee et al., 
submitted). The deer received scrapie inoculum (No.13-7) that had been passed four 
times in sheep of the ARQ/ARQ genotype [8]. A 10% w/v brain homogenate from either 
the deer cerebrum or brainstem at the level of the obex was made in phosphate 
buffered saline (PBS) with 100 µg/mL gentamicin. The high and low migration patterns 
of the two inocula sources were confirmed by western blot. The relative amounts of 
PrPSc of the two inocula sources were also quantified by enzyme immunoassay (EIA) 
(see below). EIA’s were done on samples from both brain regions at dilutions of 1:1, 
1:25, 1:50, and 1:100. Optical density (OD) values are listed in table 2. One mL of 10% 
(wt./vol.) homogenate made from either the deer cerebrum or brainstem at the level of 
the obex was oronasally inoculated into the left nostril of lambs as previously described 
[9].  
 A complete necropsy was performed on all sheep. Two tissue samples were 
taken, one to be frozen and a second to be put in 10% buffered formalin to be paraffin 
embedded and sectioned at 5 µm for staining with hematoxylin and eosin (HE) or with 
anti-prion protein antibodies. Tissue samples collected consisted of sections of brain 
(olfactory cortex, brain at the level of the optic chiasm, hippocampus, thalamus, 
midbrain, pons, cerebellum, and brainstem at the level of the obex), eye, glands 
(pituitary, salivary, adrenal), spinal cord (cervical, thoracic, lumbar), dorsal root 
ganglion, nerves (optic, sciatic, trigeminal), striated muscle (tongue, masseter, 
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diaphragm, heart), liver, lung, trachea, kidney, spleen, pancreas, skin, urinary bladder, 
intestines (ileum, jejunum, cecum), forestomachs, lymph nodes (retropharyngeal, 
mesenteric, prescapular, popliteal), tonsils (palatine and nasopharyngeal), thymus, 
thyroid, and rectal mucosa [9]. 
 Paraffin embedded sheep tissues were sectioned and stained for PrPSc by an 
automated method using a cocktail of two anti-prion protein monoclonal antibodies, 
F99/97.6.1 [10] and F89/160.1.5 [11] at a concentration of 5 µg/ml as previously 
described [9]. The morphology of the PrPSc deposits was defined as previous described 
[12]. The stellate pattern is characterized by glial-type nuclei with radiating branches of 
immunoreactivity. The term “aggregates” was used instead of “coalescing” and is 
defined as amyloid-like deposits that result in the merging of coarse particulate PrPSc 
deposits [13]. The linear pattern is observed in the neuropil and has thread-like PrPSc 
deposits in a linear form [12]. The term “granular” was used instead of the term “fine 
punctate” [12]. Granular patterning is the small, diffuse PrPSc deposits typically found in 
the neuropil [13,14]. After processing, images were captured using a Nikon DS camera 
on a Nikon Eclipse 55i microscope.  
 Frozen samples taken at necropsy were used for immunodetection of the 
abnormal prion protein by western blot (Prionics AG, Switzerland). Brainstem samples 
at the level of the obex were homogenized at a final concentration of 20% w/v in 
phosphate buffered saline (PBS). Homogenized samples were diluted 1:2 in deionized 
(DI) water prior to running on SDS-PAGE gel. The western blot was performed as 
previously described [7]. Immunodetection was done using an anti-prion protein 
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monoclonal antibody, P4 (R-Biopharm AG, Darmstadt, Germany) that targets the ovine 
prion protein at amino acids 89-104 at a final concentration of 1:10,000. 
 The BSE-Scrapie Antigen Test Kit, EIA (IDEXX, Westbrook, ME) was used on a 
20% homogenate in PBS of the brainstem at the level of the obex, cerebellum, and 
neocortex for the sheep of the current study. The test kit was also used on a 10% 
homogenate of the inocula used to challenge the sheep were assayed for PrPSc (Table 
1). The inocula (1% homogenate) used for the mouse bioassay studies were also tested 
for the relative amount of PrPSc present (Table 2). Each sample of the 10% sheep 
inoculum, 1% mouse inoculum or the 20% homogenate of the three brain regions listed 
above (Table 3) were first tested for PrPSc without being diluted (1:1). Samples were 
then diluted 1:25, 1:50, and 1:100 in PBS to determine the relative amounts of PrPSc. 
Diluted samples were then assayed on the antigen capture plate with the provided 
controls using the suggested short protocol with slight modifications. Each 100 µL 
sample received 25 µL of working plate diluent prior to being added to the plate. The 
capture plate then incubated for an hour and a half with agitation. After washing, the 
small ruminant brain conjugate concentrate (SRB-CC) was used as described and 
incubated for one hour without agitation. The antigen capture plate was then read on a 
SpectraMax 190 (Molecular Devices, Sunnyvale, CA) with an optical density of 450nm 
and a reference wavelength of 650nm. The negative sample cut-off value was 
determined by adding 0.180 to the negative control sample provided in the kit, as 
described in the protocol. Samples were deemed positive if their OD value were greater 
than the cut-off value. Since a maximum OD reading of 4.0 using EIA can result from 
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increasing levels of misfolded protein, we ran the various dilutions to determine the 
relative amount of PrPSc present in each sample.  
 Vacuolation profiles were generated by scoring the defined brain regions listed in 
Table 4 using hematoxylin and eosin stained slides. Grey matter scores were based on 
a published method: 0 = no vacuolation, 1 = occasional vacuole, 2 = several vacuoles, 
evenly distributed, 3 = moderate to many vacuoles evenly distributed, and 4 = severe 
vacuolation with possible coalescence[15]. Each score for the perspective area was 
graphed for the corresponding animal, with the exception of sheep 4 that received a 
score of 0 for each area. An average score for each area for all the sheep was 
calculated and graphed. The graph was made using GraphPad Prism 7 (GraphPad 
Software, Inc., La Jolla, CA). 
 Figure 5 provides a summary of EIA and neuropathological (vacuolation and 
IHC) results. Each circle represents a group of n = 1 (VRQ/ARR) or n = 2 (VRQ/VRQ 
and ARQ/ARQ) sheep that were inoculated with homogenate prepared from a particular 
part of the brain (cerebrum or obex at the level of the brainstem). Within a circle, each 
quadrant contains results from an individual brain region: upper left: obex; upper right, 
cerebellum grey matter; lower right: cerebellum white matter; lower left, neocortex. 
Within a quadrant, each colored sector represents the results of a test: purple, severity 
of vacuolation; green EIA optical density; and pink, distribution of PrPSc. The shade of 
the color indicates the magnitude of the test result. Severity of vacuolation: light purple, 
average vacuolation score = 1; medium purple = 1-2; dark purple = 2-3. EIA OD value: 
very light green, OD = 0.300-.500; light green, OD = .500-1.00; medium green, OD = 
1.00-2.00; dark green, OD = 2.00-4.00. Immunohistochemistry, surface area with PrPSc 
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accumulation: very light pink, PrPSc accumulation covers <10% of the neuroanatomical 
area of interest; light pink, 10-30%; medium pink, 40-60%; dark pink, 60-100%. 
 Brain material was bioassayed in transgenic mice expressing the ovine PRNP 
Tg338 (ovine, PrPVRQ) [16]. Four groups of mice were inoculated with brain homogenate 
prepared from the obex at the level of the brainstem from sheep 2 and 6 of the current 
study, a sheep inoculated with No.13-7, and a second strain of scrapie from the same 
genotype of sheep, x124 [9] (see Figure 6). EIA’s were done on the inoculum sources to 
determine the relative amounts of PrPSc as described above. OD values for each 
inoculum source are listed in Table 2. Mice (n = 17 for No.13-7, n = 20 for WTD scrapie 
sheep 2, n = 18 for WTD scrapie sheep 6, and n = 20 for x124) were inoculated by the 
intracranial route using 20 µL of a 1% (wt./vol.) brain homogenate made from sheep. 
Animal care staff monitored the mice daily for development of clinical signs. Mice were 
humanely euthanized when clinical signs of poor coordination, ataxia, difficulty moving, 
unable to move, and poor grooming with urine stained fur became apparent. Brains 
from the mice were prepared for EIA by making a 20% homogenate in PBS and 
performed as described above. Attack rates were determined by taking the number of 
mice with a positive EIA result divided by the total number of mice. Incubation periods 
were determined by taking the average incubation period of all positive mice per group. 
Survival analysis for Figure 5 was done using GraphPad Prism 7 (GraphPad Software 
Inc.). 
Results 
To determine susceptibility, Suffolk sheep were oronasally challenged with the 
scrapie agent derived from white-tailed deer. We used inoculum made from either 
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cerebrum or brainstem at the level of the obex from deer that developed scrapie after 
oronasal inoculation with the No.13-7 scrapie agent from sheep. Western blots on brain 
samples from scrapie-affected deer resulted in two different molecular profiles. Samples 
from cerebrum had scrapie-like western blot pattern that had a lower molecular mass of 
the unglycosylated band, whereas the samples derived from the obex had a CWD-like 
pattern that had a higher molecular mass of the unglycosylated band (unpublished 
observation). 
The No.13-7 scrapie agent has different incubation periods in sheep of the 
AA136 genotype compared to sheep of the VV136 genotype; all affected sheep had the 
genotype QQ171 [9]. Subsequently, sheep of three different genotypes were inoculated 
for the current study (VV136, AA136, AV136RR154QR171). Animal results are summarized 
in Table 5. Three of the five sheep inoculated with the WTD scrapie agent from deer 
cerebrum developed clinical signs of scrapie. The first two sheep to develop clinical 
signs at 28 and 31 MPI had the VV136 genotype. One sheep with the AA136 genotype 
developed disease at 48 MPI. The second sheep of the AA136 genotype (56 MPI) was 
negative by EIA, IHC, and WB. One sheep inoculated with the WTD scrapie agent from 
deer obex (genotype VV136) developed clinical signs at 65 MPI.  When compared to 
WTD scrapie-inoculated sheep in the current study, sheep challenged with original 
No.13-7 agent had a faster incubation period in sheep of the AA136 genotype (20 MPI) 
than sheep of the VV136 genotype (27 MPI) [9].  
In the present study, sheep with evidence of PrPSc accumulation in the brain also 
had PrPSc accumulation in lymphoid tissues, retina, and peripheral nervous tissue when 
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challenged with the scrapie agent from either the cerebrum or brainstem at the level of 
the obex from white-tailed deer,  (Table 5). 
To determine if the relative amounts of PrPSc in the inoculum had an influence on 
the incubation period and attack rate of inoculated sheep, each inoculum was tested by 
EIA. At equivalent dilutions, samples of deer cerebrum (shorter incubation period) had 
lower optical density values compared to samples of deer brainstem at the level of the 
obex (Table 1). Thus, the shorter incubation period in sheep inoculated with deer 
cerebrum was not due to more PrPSc in the inoculum.  
The two inoculum sources were selected based on the differences in western 
blot pattern observed in deer: deer cerebrum had a scrapie-like pattern whereas the 
deer obex at the level of the brainstem had a higher, CWD-like pattern. Brain samples 
from sheep determined positive by immunohistochemistry (sheep 1-3 and 6) also were 
positive by western blot (Figure 1). Samples from sheep negative using 
immunohistochemistry (sheep 4, 5, and 7-10) were also negative on western blot (data 
not shown).  More work will need to be done to determine the molecular mass of sheep 
challenged with the WTD scrapie agent (Figure 1).  
The PRNP genotype of the recipient sheep affected incubation period after 
challenge with the WTD scrapie agent. Potential differences in PrPSc distribution in 
sheep of different genotypes, that received different inocula, was assessed using 
immunohistochemistry with a monoclonal antibody against PrP. Sheep 1 and 2 
(genotype VV136) that were inoculated with WTD scrapie from cerebrum had intense, 
widespread immunoreactivity throughout the obex, cerebellum, and neocortex (Figure 2 
A-F). By comparison, sheep 3 (AA136) that also was inoculated with the scrapie agent 
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from deer cerebrum had less intense, but widespread PrPSc immunoreactivity (Figure 2 
G-I). Sheep 4 (AA136) was negative via IHC (Figure 2 J-L). When compared to sheep 
inoculated with WTD scrapie agent from deer cerebrum, sheep 6 (VV136) inoculated 
with the WTD scrapie agent from deer obex had less PrPSc immunoreactivity throughout 
the brain (Figure 2 M-O). Also, in contrast to VV136 sheep inoculated with the WTD 
scrapie agent from deer cerebrum, the majority of the PrPSc in the cerebellum of the 
VV136 sheep inoculated with the WTD scrapie agent from deer obex was in the 
molecular layer and no immunoreactivity was detected in the white matter. These 
results demonstrate that there are differences in PrPSc immunoreactivity between sheep 
genotypes when challenged with the same inoculum and amongst sheep of the same 
genotype when challenged with different inocula.  
To determine if the relative amounts of PrPSc were consistent with 
immunohistochemical results we used EIA to quantify PrPSc in the brainstem at the level 
of the obex, cerebellum, and neocortex (Figure 3). Optical density values from the obex 
at the dilution 1:50 were compared. Optical density values of cerebellum and neocortex 
for a 1:1 dilution were compared. EIA results for each dilution and brain region are listed 
in Table 3. Positive sheep challenged with the WTD scrapie agent from deer cerebrum 
(sheep 1, 2, and 3) had high optical density values correlating to more PrPSc present in 
the obex and cerebellum. Sheep 3 had a lower score for neocortex that was consistent 
with the immunoreactivity in Figure 2-I. Sheep 4 (AA136) tested negative in all brain 
regions. Sheep 6 (VV136) challenged with the WTD scrapie agent from deer obex had 
lower OD values for PrPSc in all brain regions when compared to sheep challenged with 
the WTD scrapie agent from deer cerebrum. These results indicate that the differences 
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in sheep genotype and inoculum source of the three sheep brain regions tested for 
PrPSc can be quantified by relative amounts of PrPSc using EIA and are consistent with 
IHC immunoreactivity in Figure 2.  
Since spongiform change is a hallmark feature of prion disease, we used 
vacuolation lesion profiling to compare the severity and distribution of disease-
associated spongiform change in the brains of sheep of the current study. Table 4 
shows the areas scored on a scale of 1-4 as previously described [15] and the results 
are plotted in Figure 4. Differences in vacuolation scores were found between sheep of 
different genotypes, for example sheep 1 (VV136) and 3 (AA136) that were both 
inoculated with the WTD scrapie agent from deer cerebrum. A difference also was 
found between sheep 1 and 6 that were sheep of the same genotype (VV136) but 
challenged with inocula derived from different brain regions of the scrapie-affected deer. 
No spongiform change was observed in sheep 4. 
Figure 5 summarizes the differences between sheep of different genotypes 
challenged with the same inoculum and sheep of the same genotype challenged with 
different inocula using three different assays: vacuolation profiling, EIA, and 
immunohistochemistry (see methods section for parameter details). 
Previous studies demonstrate that sheep of the AA136 genotype have a faster 
incubation period when inoculated with the original No.13-7 isolate [9]. In contrast, when 
sheep were challenged with a second strain of scrapie, x124, sheep of the VV136 
genotype (6.9 MPI) had a fast incubation period, and sheep of the AA136 genotype did 
not develop disease when challenged with x124 by the intranasal route [9]. The current 
study demonstrates that the WTD scrapie agent had a faster incubation period in VV136 
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sheep. To investigate the apparent change in phenotype, we used bioassay in 
transgenic mice (Tg338) that express ovine PRNP to compare attack rates and 
incubation period between the WTD scrapie inoculum and the original No.13-7 scrapie 
isolate. All scrapie strains had a 100% attack rate but with varying incubation periods. 
Mice inoculated with the WTD scrapie agent from sheep (inoculum from sheep 2 and 6, 
Table 2) had a much shorter incubation period (76 DPI; Figure 6) compared to those 
inoculated with the original No.13-7 scrapie isolate from either a VV136 (167 DPI; 
Figure 6) or an AA136 (266 DPI; not shown) sheep. Interestingly, mice inoculated with 
the WTD scrapie agent had a similar incubation period to the x124 isolate from sheep of 
the VV136 genotype (76 DPI; Figure 6). Survival analysis of ovinized mice inoculated 
with No.13-7 scrapie, WTD scrapie, and x124 demonstrates that the WTD scrapie agent 
is significantly shorter than the No.13-7 isolate (p-value <0.0001) and not different from 
the x124 isolate (p-value >0.9999).  
Since the incubation period in sheep challenged with WTD scrapie or x124 was 
faster in VV136 sheep compared to AA136 sheep, we used immunohistochemistry to 
compare PrPSc accumulation in No.13-7 [9], WTD scrapie, or x124 [9] challenged 
VV136 sheep. All inocula had similar widespread accumulation in the obex (Figure 7 A, 
D, G). Differences in the intensity of immunoreactivity in the cerebellum and neocortex 
between inocula groups were notable. Sheep inoculated with No.13-7 had less 
extensive PrPSc immunoreactivity in the cerebellum compared to the cerebella of sheep 
inoculated with WTD scrapie or x124 (Figure 7 B, E, H). There was little 
immunoreactivity in the molecular layer of the cerebella of sheep inoculated with No.13-
7, whereas sheep inoculated with either WTD scrapie or x124 had intense, widespread 
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immunoreactivity. There was less PrPSc deposition in the granular layer of the cerebella 
in No.13-7 challenged sheep compared to WTD scrapie or x124 challenged sheep. 
Stellate, small aggregates, linear, and granular labeling are present in neocortical layers 
I-III and V of WTD scrapie inoculated sheep and not present in No.13-7 inoculated 
sheep (Figure 7 C, F, I). Granular and linear labeling was not as prominent in layer IV of 
No.13-7 inoculated sheep compared to WTD scrapie or x124 inoculated sheep. WTD 
scrapie and x124 challenged sheep also had intense immunoreactivity of PrPSc in layer 
IV of the neocortex compared to No.13-7 inoculated sheep that had mild 
immunoreactivity in this layer. PrPSc deposition also was present in neocortical white 
matter of WTD scrapie or x124 sheep, whereas it was absent in the No.13-7 sheep 
(Figure 7). These results indicate that there are changes in immunoreactivity after the 
No.13-7 scrapie isolate has been passaged through deer. Furthermore, sheep 
challenged with WTD scrapie had similar PrPSc immunoreactivity patterns to sheep 
challenged with x124. 
Discussion 
A summary of the serial passage of the No.13-7 scrapie isolate to sheep in the 
current study is shown in Figure 8. The US No.13-7 scrapie isolate was passaged four 
times by the intracranial route in sheep of the AA136 genotype [8]. One sheep from this 
passage group was used to challenge white-tailed deer by the oronasal route (Greenlee 
submitted). Two brain regions from these deer (cerebrum and brainstem at the level of 
the obex) had different molecular weight profiles by western blot. In the current study, 
samples of brainstem and cerebrum from scrapie-affected deer were used to challenge 
Suffolk sheep by the oronasal route.  
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Sheep Are Susceptible to the Scrapie Agent Derived From White-tailed 
Deer 
The first sheep to develop disease were challenged with the scrapie agent 
derived from deer cerebrum. In this challenge group, sheep of the VV136 genotype 
developed disease faster than sheep of the AA136 genotype. Only one of the five sheep 
challenged with the scrapie agent derived from deer brainstem at the level of the obex 
developed clinical signs and this sheep had the VV136 genotype. Overall, only one of 
the four sheep with the AA136 genotype developed disease. We previously reported 
that in sheep inoculated with the US No.13-7 scrapie isolate all sheep develop clinical 
signs. Sheep of the AA136 genotype develop disease faster than sheep of the VV136 
genotype [9]. Therefore, passage of the US No.13-7 scrapie isolate through white-tailed 
deer results in a change in disease phenotype with sheep of the VV136 genotype 
developing disease faster than sheep of the AA136 genotype.  
Sheep of the AV136QR171 genotype challenged with either cerebrum or brainstem 
at the level of the obex from deer failed to develop disease. These results are similar to 
findings of sheep with the AV136QR171 (0 out of 2) or AA136QR171 (0 out of 3) genotype 
challenged with BSE isolates [3]. It has also been reported that sheep of the AA136QR171 
genotype do not develop disease or PrPSc accumulation when challenged by the 
oronasal route with the No. 13-7 scrapie isolate [17]. The findings combined are 
consistent with the presence of arginine (R) at this position (171) providing more 
resistance to disease [3].  
We have shown that the transmission of the scrapie agent derived from white-
tailed deer is possible by the oronasal route. In addition, passage of the US No.13-7 
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scrapie isolate through white-tailed deer results in a disease phenotype switch. The US 
No.13-7 scrapie isolate has a more rapid incubation period in sheep of the AA136 
genotype prior to passage in deer. In contrast, the scrapie agent that results after 
passage in deer has a more rapid incubation period in sheep of the VV136 genotype.    
The Phenotype Switch After Passage Through Deer Is Associated with 
New Sheep Genotype Susceptibilities 
We observed a change in disease phenotype as a shortened incubation period in 
sheep of the VV136 genotype after the scrapie agent was passaged in deer. Sheep of 
the VV136 genotype developed disease faster than sheep of the AA136 genotype. A 
possible explanation for this phenotype change in sheep can be supported by previous 
work that reported on the susceptibility of sheep to mule deer CWD [18]. In that study, 
only 1 out of the 8 sheep of the AV136 genotype (AA136QR171 n = 4; AA136QQ171 n = 3; 
AV136QQ171 n = 1) challenged by the intracranial route with mule deer CWD developed 
clinical signs and detectable PrPSc. It was suggested that susceptibility of sheep to 
CWD might be partially dependent on valine (V) at codon 136. This is because the 
sheep that had evidence of PrPSc and clinical signs had the genotype AV136 and was 
the only one from the study with a valine (V) at codon 136 [18]. 
The Transmission of CWD To Sheep Is Less Efficient Than The 
Transmission of Scrapie to Deer 
 Sheep are not very susceptible to white-tailed deer CWD. To date, oronasal 
challenge with white-tailed deer CWD has been unsuccessful (current study at 50 MPI). 
CWD from either elk or mule deer into sheep was unsuccessful or had a low attack rate 
after intracerebral inoculation [18, 19]. In addition, there was no transmission of elk 
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CWD to sheep by the oronasal route [19]. Whereas, a low attack rate (2 out of 10) was 
found in sheep challenged IC with mule deer CWD [18]. These findings also are 
consistent with other reports that used transgenic ovinized mice. Tg338 mice (ovine 
PRNP; VRQ) did not develop disease when challenged with white-tailed deer CWD [20]. 
In addition, there was ineffective transmission of CWD to transgenic mice expressing 
ovine PRNP (Tg338) whether it was derived from elk, mule deer, or white-tailed deer 
[21]. Failure to develop CWD after oral exposure and low attack rates after IC 
inoculation supports the conclusion that sheep are not highly susceptible to CWD. 
White-tailed deer are highly susceptible to the sheep scrapie agent. A 100% 
attack rate has been reported in white-tailed deer inoculated with No. 13-7 when 
intracranially [7] or oronasally (Greenlee submitted) inoculated. White-tailed deer also 
have a 100% attack rate when challenged by the intravenous route with the SSBP/1 
scrapie isolate [22]. Conversely, there was no transmission of the sheep scrapie agent 
to cervidized mice when challenged with a naturally acquired strain of scrapie [20]. 
Interestingly, inoculum from sheep challenged by the intracranial route with elk CWD 
had efficient transmission to both ovinized and cervidized mice [20]. The findings 
combined suggest that transmission of the agents of prion disease between sheep and 
deer is one-way. That is, sheep have low susceptiblity to the CWD agent but deer are 
highly susceptible to the scrapie agent.  
Differences in Patterns of Immunoreactivity were Notable Between Sheep 
Genotypes and Inoculum Sources 
Sheep of the VV136 genotype inoculated with the scrapie agent from deer 
cerebrum had more PrPSc immunoreactivity in the cerebellum and neocortex compared 
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to sheep of the AA136 genotype. However, previous work in sheep challenged with the 
original No.13-7 isolate described much less extensive immunoreactivity in the 
neocortex of sheep with the VV136 genotype in comparison to sheep of the AA136 
genotype [9]. This is consistent with immunoreactivity differences described in cases of 
naturally and experimentally challenged scrapie. PrPSc patterns demonstrated by 
immunohistochemistry were found to be different between sheep of the AA136 and 
VV136 genotypes in cases of natural scrapie [25-27]. Sheep with the AA136 genotype 
had predominately punctate patterning in the dorsal motor nucleus of the vagus nerve, 
whereas sheep of the VV136 genotype had predominately granular and coalescing 
patterning in the dorsal motor nucleus of the vagus nerve [25]. When comparing Welsh 
Mountain sheep of the VV136 genotype to Suffolk sheep of the AA136 genotype 
naturally infected with scrapie, sheep of the VV136 genotype had more vascular plaque 
PrPSc accumulation throughout the brain, whereas sheep of the AA136 genotype had 
more astrocyte-associated and neuropil PrPSc accumulation [26]. Differences in 
immunohistochemistry PrPSc patterns also were found in sheep orally challenged with 
scrapie. Sheep of the VV136 genotype had prominent neuronal and glial intracellular 
aggregates, whereas sheep of the AA136 genotype presented with more stellate and 
astrocyte-associated types and no glia-associated aggregates [27]. Consistent with 
these findings, the present study demonstrates that experimental transmission by the 
oronasal route can result in immunoreactivity differences between sheep genotypes.  
Differences in the amount of PrPSc immunoreactivity were observed in sheep of 
the same genotype when challenged with different inocula sources. Sheep with the 
VV136 genotype challenged with the scrapie agent derived from deer cerebrum had 
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extensive PrPSc in the obex, cerebellum, and neocortex. In contrast, sheep (VV136) 
challenged with the scrapie agent from deer obex that had less immunoreactivity in 
these areas. We also noted differences in immunoreactivity in brain regions of sheep of 
the VV136 genotype when challenged with two different inocula, No.13-7 and x124 [9]. 
The differences in immunoreactivity between sheep genotypes and inocula source 
supports our conclusion that a change in phenotype occurs after the original No. 13-7 
scrapie isolate was passaged through deer.  
Passage of the No.13-7 Scrapie Agent Through Deer Results in Shorter 
Incubation Periods in Ovinized Mice  
The ovinized mouse line, Tg338, is established for studying the biological 
behavior of scrapie and CWD isolates [20-21, 28-32]. Our most surprising result was the 
shortened incubation period of the No.13-7 isolate after passage through deer. This 
shorter incubation period was similar to another US scrapie isolate, x124, in ovinized 
mice. The x124 scrapie isolate has a rapid incubation time in sheep with the VV136 
genotype [9, 33]. The shorter incubation period in ovinized mice inoculated with the 
WTD scrapie agent compared to the relatively long incubation period observed in mice 
inoculated with the No.13-7 sheep scrapie isolate provides further evidence of a 
phenotype switch from the No.13-7 scrapie isolate after passage through deer.  
Passage of No.13-7 Through White-tailed Deer Results in a Phenotype 
Similar to x124 
The bioassay findings led us to compare PrPSc immunoreactivity between VV136 
sheep challenged with the No.13-7, WTD scrapie, or x124 agent. We found that sheep 
inoculated with WTD scrapie sheep had more PrPSc immunoreactivity in the obex, 
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cerebellum, and neocortex, which was in contrast to sheep inoculated with No.13-7. 
Similar immunoreactivity patterns were observed in the brains of sheep inoculated with 
WTD scrapie and x124. We previously described differences in PrPSc immunoreactivity 
patterns in VV136 sheep challenged with x124 or No.13-7 scrapie isolates [9].  
These results indicate that passage of sheep scrapie through WTD leads to a 
change in disease phenotype. This phenotype switch is observed as different 
immunoreactivity levels and PrPSc accumulation patterns in sheep challenged with the 
WTD scrapie agent compared to sheep challenged with the original No.13-7 scrapie 
isolate. A change in disease phenotype is also supported by results of bioassay in 
transgenic mice expressing ovine PRNP that results in a shorted incubation period of 
the No.13-7 scrapie isolate after it was passaged in deer.  
Conclusions 
Sheep are susceptible to the scrapie agent derived from white-tailed deer when 
challenged by the oronasal route. Passage of the sheep-derived US No. 13-7 scrapie 
isolate through white-tailed deer results in a change in disease phenotype that is 
observed when the deer-passaged scrapie is inoculated back into sheep or ovinized 
mice. In sheep, the relationship between incubation period and genotype is reversed; 
the original No.13-7 scrapie isolate produces a shorter incubation period in AA136 
sheep compared to VV136 sheep, while the deer-passaged scrapie isolate results in a 
shorter incubation period in VV136 sheep. In addition, passage of the No.13-7 isolate 
through deer results in a change in the pattern of PrPSc deposition in the brain such that 
the PrPSc patterns in VV136 sheep challenged with WTD scrapie look similar to x124. 
The results indicate that if there is contact between scrapie-infected deer and sheep, 
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there is the potential for reinfection of sheep with deer-derived scrapie. Furthermore, 
interspecies transmission of the scrapie agent can result in a phenotype switch that 
differs from the original inoculum and potentially promote the generation of new scrapie 
strain properties.  
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Table 1. EIA optical densities of the WTD scrapie inocula 
Dilution 
Deer 
Cerebrum Deer Obex 
1:1 4 4 
1:25 0.999 4 
1:50 0.611 2.46 
1:100 0.399 1.925 
 
Samples of inoculum from either deer cerebrum or deer obex inocula samples were 
assayed on EIA in the following increasing dilutions to determine the relative amount of 
PrPSc in each sample. 
 
Table 2. EIA optical densities of the mouse bioassay inocula 
Dilution No.13-7 Sheep 2 x124 Sheep 6 
1:1 4 3.926 4 2.006 
1:25 3.701 3.427 3.04 0.195 
1:50 3.176 2.917 3.441 0.167 
1:100 2.156 1.854 2.354 0.125 
 
The inocula for mouse bioassay derived from sheep infected with No.13-7, WTD scrapie 
sheep 2, x124, and WTD scrapie sheep 6 used as inoculum source for mouse bioassay 
were tested via EIA in increasing dilutions to determine the relative amount of PrPSc. 
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Table 3. EIA optical densities of brain regions of sheep infected with the scrapie 
agent from WTD 
 
 
Samples from the brainstem at the level of the obex, cerebellum, and neocortex of the 
animals tested for PrPSc immunoreactivity in Figure 2 were quantified using EIA in 
increasing dilutions to determine the relative amount of PrPSc present in each brain 
region. 
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Table 4. Brain regions scored for spongiform change 
Neuroanatomical	area	 Area	Code	
Nucleus	of	the	solitary	tract	 1	
Nucleus	of	the	spinal	tract	of	V	 2	
Hypoglossal	nucleus	 3	
Vestibular	nuclear	complex	 4	
Cochlear	nucleus	 5	
Cerebellar	vermis	 6	
Central	grey	matter		 7	
Rostral	colliculus	 8	
Medial	geniculate	nucleus	 9	
Hypothalamus	 10	
Nucleus	dorsomedialis	thalami	 11	
Nucleus	ventralis	lateralis	thalami	 12	
Frontal	cortex	 13	
Septal	nuclei	 14	
Caudate	Nucleus		 15	
Putamen	 16	
Claustrum	 17	
 
Each brain region has a corresponding area code. Perspective score for each animal is 
shown in Figure 4. 
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Table 5. PrPSc distribution in sheep inoculated with the scrapie agent derived 
from white-tailed deer 
 
Sheep 
Number 
Genotype 
Codon 
136 Inoculum  
Incubation 
Period 
(MPI) 
Clinical 
Signs  L
R
S
 h
ea
d 
 
LR
S
 o
th
er
 
R
ec
ta
l 
R
et
in
a 
 
P
N
S
 
1 VV Cerebrum 31 + + + + + + 
2 VV Cerebrum 28 + + + + + + 
3 AA Cerebrum 48 + + + + - + 
4 AA Cerebrum 56 - - - - - - 
5 AV Cerebrum 72 -  - - - - - 
                    
6 VV Obex 65 + + - + + + 
7 VV Obex 72  - - - - - - 
8 AA Obex 72 - - - - - - 
9 AA Obex 72 - - - - - - 
10 AV Obex 72 - - - - - - 
 
Animal data, incubation period, presence of clinical signs at death, and PrPSc 
distribution for lymphoid tissues and non-brain nervous tissue.  
Abbreviations: Residue at codon 136 of the PRNP - V: valine, A; alanine. Months post-
inoculation (MPI). LRS: lymphoreticular system. PNS: peripheral nervous system tissue, 
CNS: central nervous system.   
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Figure 1. Western blot of brainstem samples from sheep with clinical signs after 
inoculation with the WTD scrapie agent. Western blot comparison of sheep samples 
inoculated with WTD scrapie to the original No.13-7 scrapie inoculum and deer CWD. 
Monoclonal antibody P4 was used for the detection of PrPSc. Marker = molecular mass 
marker. 
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Figure 2. PrPSc deposition in brain regions varies with sheep PRNP genotype and 
source of inoculum. Sheep with immunoreactivity were euthanized at similar stages of 
clinical disease. Sheep 1 (A-C), sheep 2 (D-F), sheep 3 (G-I), sheep 4 (J-L), and sheep 
6 (M-O). The two VRQ/VRQ sheep inoculated with the WTD scrapie agent from 
cerebrum (sheep 1 and 2) had intense widespread immunoreactivity in the brainstem at 
the level of the obex (A,D), cerebellum (B,E), and neocortex (C,F). An ARQ/ARQ sheep 
inoculated with the WTD scrapie agent from cerebrum (sheep 3) had less intense but 
widespread accumulation in the obex (G), cerebellum (H), and neocortex (I). 
Representative brain regions of ARQ/ARQ (sheep 4) were negative by EIA, WB, and 
IHC (J-L). A VRQ/VRQ sheep inoculated with the WTD scrapie agent from obex (sheep 
6) had mild PrPSc accumulation in the obex (M), cerebellum (N), and neocortex (O).  
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Figure 3. Quantitative analysis of PrPSc present in brainstem, cerebellum, and 
neocortex. Differences in the amount of PrPSc present in brain regions observed by 
IHC (Figure 2) can be assessed using EIA. The VRQ/VRQ sheep (sheep 1 and 2) have 
high OD values in all three sheep brain regions. The positive ARQ/ARQ sheep (sheep 
3) had high OD values for obex and cerebellum but a lower score for the neocortex 
compared to VRQ sheep that received the same inoculum. The ARQ/ARQ sheep 
(sheep 4) without immunoreactivity by IHC also was negative by EIA in all three brain 
regions. A VRQ/VRQ sheep challenged with the scrapie agent from deer obex (sheep 
6) was positive by EIA but with low OD values relative to sheep challenged with 
inoculum from deer cerebrum.  
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Figure 4. Gray matter vacuolation profiles for sheep inoculated with the WTD 
scrapie agent. Area codes for specific brain regions are defined in Table 4. Variations 
in vacuolation scores between sheep of different genotypes challenged with same 
inoculum and between sheep of the same genotype challenged with different inocula. 
Similar vacuolation scores were seen in VRQ/VRQ sheep that received WTD cerebrum 
(sheep 1 and 2). A ARQ/ARQ sheep (sheep 3) and the VRQ/VRQ sheep (sheep 6) 
inoculated with WTD obex had lower vacuolation scores compared to the VRQ/VRQ 
sheep challenged with WTD cerebrum. Differences were seen between sheep 1 and 3 
and between sheep 1 and 6. Sheep 4 was left out of figure due to all areas receiving a 
score of 0 for vacuolation.  
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Figure 5. Association of vacuolation, EIA, and immunohistochemistry data with 
results by sheep genotype and inoculum source. This summary demonstrates that 
differences can be seen between sheep of different genotypes challenged with the 
same inoculum and sheep of the same genotype challenged with different inocula. Each 
quadrant represents a brain region tested (obex, cerebellum grey matter, cerebellum 
white matter, or neocortex). Each wedge in the quadrant is a different test (vacuolation, 
EIA, or IHC). The color of the wedge represents the severity of the results from each 
test, where lower scores received a lighter shade and higher scores received a darker 
shade. Legend line key: 1) sheep genotype 2) inocula source 3) sheep represented 4) 
attack rate. Sheep 4 and 7 were negative and not diagramed.  
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Figure 6. The incubation period of  ovinized transgenic mice (Tg338) challenged 
with No.13-7 inoculum from sheep of the VV136 genotype was reduced after 
passage through deer. The incubation period of mice inoculated with WTD scrapie 
from sheep was shorter than the original No.13-7 inoculum and was similar to the 
incubation period of 76 days post-inoculation (DPI) to that of another strain of scrapie 
strain, x124. All inocula were from sheep with the VRQ/VRQ genotype.  
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Figure 7. Comparison of PrPSc accumulation in various brain regions of VV136 
sheep challenged with the scrapie agent from different sources. PrPSc distribution 
differences are noticeable in various brain regions of sheep inoculated with different 
scrapie isolates. The original No.13-7 scrapie inoculum in sheep is represented in 
figures A, B, C. WTD scrapie in sheep 2, has more PrPSc labeling in the cerebellum (E) 
and neocortex (F) compared to No.13-7 (B, C) and also similar, but less, labeling to 
x124 (Hamir, Vet Pathol 2009) (G, H, I).  
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Figure 8. Summary of serial passage of the original No.13-7 scrapie isolate.  
The original No.13-7 scrapie isolate was passaged four times by the intracranial route in 
sheep of the ARQ/ARQ genotype prior to its oronasal challenge in WTD. Inocula 
derived from cerebrum or obex sample from a deer with clinical signs was used to 
oronasally challenge sheep of various genotypes. The first two sheep to develop clinical 
signs (29 MPI) were challenged with the scrapie agent from deer cerebrum and had the 
VRQ/VRQ genotype. One ARQ/ARQ sheep challenged with deer cerebrum also 
developed disease but at 48 MPI. Sheep challenged with the scrapie agent from deer 
obex tested positive for PrPSc but with an extended incubation period of 65 MPI. Also 
shown is the inoculation route from WTD scrapie challenged sheep to Tg338 mice 
expressing ovine PrP. The mouse passage results can be found in Figure 5 of the 
current study.  
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CHAPTER 3. GENERAL CONCLUSIONS 
Summary 
 The purpose of this work was to better understand the potential for interspecies 
transmission of TSEs between sheep and deer. I characterized the disease phenotype 
by looking at PrPSc accumulation intensities and pattern of deposition, incubation period, 
spongiform change, and the molecular mass of the misfolded prion protein. TSEs can 
result in different disease phenotypes depending on the recipient species and its PRNP 
polymorphisms. Here, I demonstrate how interspecies transmission can influence 
disease phenotype. 
 In chapter 2, I report results of work to determine if sheep were susceptible to 
oronasal challenge of the scrapie agent derived from white-tailed deer. It has been 
demonstrated that deer are readily susceptible to the agent of sheep scrapie, but sheep 
are not very susceptible to CWD. When white-tailed deer were challenged with the 
sheep scrapie agent, western blot analysis revealed two different molecular mass 
profiles from different brain regions. The cerebrum had a scrapie-like molecular mass, 
whereas the brainstem at the level of the obex had a CWD-like molecular mass. 
Because of these differences, sheep were challenged with brain homogenate made 
from either the cerebrum or the brainstem at the level of the obex. I determined that 
sheep are susceptible to the scrapie agent derived from white-tailed deer. I found that 
sheep of the VV136 genotype had a disease phenotype that differed from the original 
sheep scrapie isolate. When challenged with the original No.13-7 sheep-derived isolate, 
sheep of the AA136 genotype had the fastest incubation period. However, challenge of 
VV136 sheep with the deer-derived scrapie isolate resulted in a faster incubation period 
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than sheep of the AA136 genotype. Differences that further support a phenotype 
change includes PrPSc accumulation intensity and spongiform change between sheep of 
different genotypes challenged with the same inoculum and sheep of the same 
genotype challenged with different inocula. When sheep brain homogenate was 
bioassayed in transgenic mice expressing ovine PRNP, the WTD scrapie agent had a 
much shorter incubation period compared to the original sheep scrapie isolate.  
 I have identified that interspecies transmission of scrapie resulted in a disease 
phenotype switch that differs from the original source. The phenotype switch in sheep 
after passage through deer suggests interspecies transmission could generate new 
prion strain properties. This is of concern because scrapie-infected deer could pose as 
a risk for scrapie eradication programs. Since wild deer cannot be contained and can 
act as a host for the scrapie agent, it is important to characterize this potential new 
strain of scrapie that produces a new disease phenotype in sheep of different 
genotypes. Furthermore, scrapie-infected deer could carry infectivity back into 
geographical locations thought to be free from scrapie in sheep and goats. 
Future Research  
 I have demonstrated that a phenotype switch occurred when sheep scrapie was 
passaged through deer and back to sheep. In order to characterize this new isolate, it is 
necessary to serially pass the WTD scrapie agent in sheep. A second passage of the 
WTD scrapie agent already has been done using inoculum made from a VV136 sheep 
and an AA136 sheep from the current work. Stabilization and characterization of this 
scrapie strain in sheep would allow us to be able to differentiate between a WTD 
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scrapie-infected sheep and a sheep infected with classical scrapie if there were to be an 
outbreak. 
 In order to classify this as a new strain of scrapie, it also will be necessary to 
pass the agent in strain typing mice. Briefly, this requires serial passage in three 
different strains of mice that would then make it possible to compare it to the original 
sheep scrapie isolate by comparison of incubation period and by lesion profiling. I would 
compare the incubation periods, PrPSc accumulation patterns and intensity, and 
spongiform change. 
 Passage of the WTD scrapie agent from sheep back to white-tailed deer would 
allow us to compare the disease phenotype of these deer to deer infected with CWD 
and to deer challenged with the original sheep scrapie agent (No.13-7). I would 
compare incubation periods, PrPSc immunoreactivity and molecular mass profiles. This 
work will further characterize the WTD scrapie agent. In addition, it would give us insight 
to multiple interspecies transmission events and the affect it would have on disease 
presentation.  
Concluding Remarks 
 This thesis work addresses the concerns of the potential interspecies 
transmission of TSEs between sheep and deer. Using techniques to identify and 
differentiate between TSEs, we were able to demonstrate that a scrapie-infected deer 
could transmit the disease back to sheep. Furthermore, infected sheep presented with a 
disease with different characteristics than the original scrapie isolate. By demonstrating 
the differences between the original sheep scrapie isolate and the WTD scrapie agent, I 
	 72	
have provided insight into the ability of a TSE strain to change its properties after 
interspecies transmission.  
 
